<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00444457</url>
  </required_header>
  <id_info>
    <org_study_id>6096A1-3005</org_study_id>
    <nct_id>NCT00444457</nct_id>
  </id_info>
  <brief_title>Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants</brief_title>
  <official_title>A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <brief_summary>
    <textblock>
      The purpose of this study will be to evaluate safety, tolerability and immunogenicity of
      three lots of 13-valent pneumococcal vaccine given to healthy infants. Lots will be studied
      for consistency of the immune response, as well as for non-inferiority and safety as compared
      to 7-valent Pneumococcal Conjugate Vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in the Three 13vPnC Groups 1 Month After the Infant Series</measure>
    <time_frame>1 Month after the infant series (7 Months of age)</time_frame>
    <description>Antibody geometric mean concentration (GMC) as measured by micrograms per milliliter (mcg/mL) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Predefined Antibody Level ≥0.1 International Units Per Milliliter (IU/mL) for Tetanus Toxoid in the Combined 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series</measure>
    <time_frame>1 month after the infant series (7 months of age)</time_frame>
    <description>Percentage of participants achieving predefined antibody threshold ≥0.1 IU/ mL along with the corresponding 95% CI for concomitant antigen tetanus toxoid are presented. Exact 2-sided CI was based on the observed proportion of participants. Combined 13vPnC group includes participants randomized to pilot lot 1, pilot lot 2, or the manufacturing lot.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Predefined Antibody Level ≥1:8 for Poliovirus in the Combined 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series</measure>
    <time_frame>1 month after the infant series (7 months of age)</time_frame>
    <description>Percentage of participants achieving predefined antibody threshold ≥1:8 along with the corresponding 95% CI for concomitant antigen poliovirus type 1, type 2, and type 3 (Sabin strains 1, 2, 3) are presented. Exact 2-sided CI was based on the observed proportion of participants. Combined 13vPnC group includes participants randomized to pilot lot 1, pilot lot 2, or the manufacturing lot.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Predefined Antibody Level ≥10.0 Milli-International Units Per Milliliter (mIU/mL) for Hepatitis B in the Combined 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series</measure>
    <time_frame>1 month after the infant series (7 months of age)</time_frame>
    <description>Percentage of participants achieving predefined antibody threshold ≥10.0 mIU/ mL along with the corresponding 95% CI for concomitant antigen hepatitis B are presented. Exact 2-sided CI was based on the observed proportion of participants. Combined 13vPnC group includes participants randomized to pilot lot 1, pilot lot 2, or the manufacturing lot.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.35 Mcg/mL in the Three 13vPnC Groups 1 Month After the Infant Series</measure>
    <time_frame>1 month after the infant series (7 months of age)</time_frame>
    <description>Percentage of participants achieving predefined antibody threshold ≥0.35mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.35 Mcg/mL in the Three 13vPnC Groups 1 Month After the Toddler Dose</measure>
    <time_frame>1 month after the toddler dose (13 months of age)</time_frame>
    <description>Percentage of participants achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥1.00 Mcg/mL in the Combined 13vPnC Group 1 Month After the Infant Series</measure>
    <time_frame>1 month after the infant series (7 months of age)</time_frame>
    <description>Percentage of participants achieving predefined antibody threshold ≥1.00 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥1.00 Mcg/mL in the Three 13vPnC Groups 1 Month After the Toddler Dose</measure>
    <time_frame>1 month after the toddler dose (13 months of age)</time_frame>
    <description>Percentage of participants achieving predefined antibody threshold ≥1.00 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in the Three 13vPnC Groups 1 Month After the Toddler Dose</measure>
    <time_frame>1 month after the toddler dose (13 months of age)</time_frame>
    <description>Antibody geometric mean concentration (GMC) as measured by mcg/mL for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of Participants Reporting Local Reactions in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 1 (2 Months of Age)</measure>
    <time_frame>Within 7 days after dose (2 months of age)</time_frame>
    <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Participants may be represented in more than 1 category.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants Reporting Local Reactions in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 2 (4 Months of Age)</measure>
    <time_frame>Within 7 days after dose (4 months of age)</time_frame>
    <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 cm to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Participants may be represented in more than 1 category.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants Reporting Local Reactions in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 3 (6 Months of Age)</measure>
    <time_frame>Within 7 days after dose (6 months of age)</time_frame>
    <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 cm to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Participants may be represented in more than 1 category.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants Reporting Local Reactions in the Combined 13vPnC Group and 7vPnC Group: Toddler Dose (12 Months of Age)</measure>
    <time_frame>Within 7 days after dose (12 months of age)</time_frame>
    <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 cm to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Participants may be represented in more than 1 category.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants Reporting Systemic Events in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 1 (2 Months of Age)</measure>
    <time_frame>Within 7 days after dose (2 months of age)</time_frame>
    <description>Systemic events (any fever ≥ 38 degrees Celsius [C], decreased appetite, irritability, increased sleep, decreased sleep, and hives [urticaria]) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants Reporting Systemic Events in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 2 (4 Months of Age)</measure>
    <time_frame>Within 7 days after dose (4 months of age)</time_frame>
    <description>Systemic events (any fever ≥ 38 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives [urticaria]) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants Reporting Systemic Events in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 3 (6 Months of Age)</measure>
    <time_frame>Within 7 days after dose (6 months of age)</time_frame>
    <description>Systemic events (any fever ≥ 38 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives [urticaria]) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants Reporting Systemic Events in the Combined 13vPnC Group and 7vPnC Group: Toddler Dose (12 Months of Age)</measure>
    <time_frame>Within 7 days after dose (12 months of age)</time_frame>
    <description>Systemic events (any fever ≥ 38 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives [urticaria]) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1712</enrollment>
  <condition>Vaccines, Pneumococcal</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13-valent Pneumococcal Conjugate Vaccine</intervention_name>
    <description>0.5 mL of study vaccine administered IM at 2, 4, 6, and 12 months of age.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>7vPnC</intervention_name>
    <description>0.5 mL of study vaccine administered IM at 2, 4, 6, and 12 months of age.</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Healthy 2 month old infants

          -  Available for the duration of the study and reachable by telephone

          -  Able to complete two blood drawing procedures during the study

        Exclusion criteria:

          -  Previous vaccination, contraindication or history of allergic reaction to vaccines or
             vaccine components

          -  Bleeding disorder, immune deficiency or significant chronic or congenital disease

          -  Previous receipt of blood products or immune globulin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>42 Days</minimum_age>
    <maximum_age>98 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Benton</city>
        <state>Arkansas</state>
        <zip>72019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Conway</city>
        <state>Arkansas</state>
        <zip>72033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>North Little Rock</city>
        <state>Arkansas</state>
        <zip>72117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Downey</city>
        <state>California</state>
        <zip>90242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fontana</city>
        <state>California</state>
        <zip>92335</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lakewood</city>
        <state>California</state>
        <zip>90805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moreno Valley</city>
        <state>California</state>
        <zip>92557</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rolling Hills Estates</city>
        <state>California</state>
        <zip>90274</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Longmont</city>
        <state>Colorado</state>
        <zip>80501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palm Beach Gardens</city>
        <state>Florida</state>
        <zip>33410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Woodstock</city>
        <state>Georgia</state>
        <zip>30189</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nampa</city>
        <state>Idaho</state>
        <zip>83686</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dekalb</city>
        <state>Illinois</state>
        <zip>60115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Crestview Hills</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <zip>02124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jamaica Plain</city>
        <state>Massachusetts</state>
        <zip>02130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Whitehouse Station</city>
        <state>New Jersey</state>
        <zip>08809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fishkill</city>
        <state>New York</state>
        <zip>12524</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hopewell Jct</city>
        <state>New York</state>
        <zip>12533</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ithaca</city>
        <state>New York</state>
        <zip>14850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sylva</city>
        <state>North Carolina</state>
        <zip>28779</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bismark</city>
        <state>North Dakota</state>
        <zip>58501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45245</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huber Heights</city>
        <state>Ohio</state>
        <zip>45424</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <zip>45429</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mason</city>
        <state>Ohio</state>
        <zip>45040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kittanning</city>
        <state>Pennsylvania</state>
        <zip>16201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Latrobe</city>
        <state>Pennsylvania</state>
        <zip>15650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clarksville</city>
        <state>Tennessee</state>
        <zip>37043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>37067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>South Jordan</city>
        <state>Utah</state>
        <zip>84095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vienna</city>
        <state>Virginia</state>
        <zip>22180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98664</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98686</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>LaCrosse</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monroe</city>
        <state>Wisconsin</state>
        <zip>53566</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2007</study_first_submitted>
  <study_first_submitted_qc>March 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2007</study_first_posted>
  <results_first_submitted>June 11, 2010</results_first_submitted>
  <results_first_submitted_qc>June 11, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 14, 2010</results_first_posted>
  <last_update_submitted>October 10, 2012</last_update_submitted>
  <last_update_submitted_qc>October 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccine</keyword>
  <keyword>Infants</keyword>
  <keyword>Pneumococcal Conjugate Vaccines</keyword>
  <keyword>Vaccines, Pneumococcal</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>13vPnC (Pilot Lot 1)</title>
          <description>Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1 at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.</description>
        </group>
        <group group_id="P2">
          <title>13vPnC (Pilot Lot 2)</title>
          <description>Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 2 at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.</description>
        </group>
        <group group_id="P3">
          <title>13vPnC (Manufacturing Lot)</title>
          <description>Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) manufacturing lot (manu lot) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.</description>
        </group>
        <group group_id="P4">
          <title>7vPnC</title>
          <description>Participants received 1 single 0.5 milliliter (mL) dose of 7-valent pneumococcal conjugate vaccine (7vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Infant Series</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="489"/>
                <participants group_id="P2" count="488"/>
                <participants group_id="P3" count="489"/>
                <participants group_id="P4" count="246"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 1</title>
              <participants_list>
                <participants group_id="P1" count="486"/>
                <participants group_id="P2" count="484"/>
                <participants group_id="P3" count="485"/>
                <participants group_id="P4" count="244"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 2</title>
              <participants_list>
                <participants group_id="P1" count="455"/>
                <participants group_id="P2" count="447"/>
                <participants group_id="P3" count="455"/>
                <participants group_id="P4" count="228"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 3</title>
              <participants_list>
                <participants group_id="P1" count="442"/>
                <participants group_id="P2" count="435"/>
                <participants group_id="P3" count="438"/>
                <participants group_id="P4" count="225"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="435"/>
                <participants group_id="P2" count="427"/>
                <participants group_id="P3" count="428"/>
                <participants group_id="P4" count="218"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="61"/>
                <participants group_id="P3" count="61"/>
                <participants group_id="P4" count="28"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Parent or legal guardian request</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="34"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed to return</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator request</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>After Infant Series</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="435"/>
                <participants group_id="P2" count="427"/>
                <participants group_id="P3" count="427"/>
                <participants group_id="P4" count="218"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="415">Not completed=Withdrawn after infant series</participants>
                <participants group_id="P2" count="397">Not completed=Withdrawn after infant series</participants>
                <participants group_id="P3" count="408">Not completed=Withdrawn after infant series</participants>
                <participants group_id="P4" count="208">Not completed=Withdrawn after infant series</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Parent or legal guardian request</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed to return</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator request</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Toddler Dose</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="415">Vaccinated toddler dose</participants>
                <participants group_id="P2" count="397">Vaccinated toddler dose</participants>
                <participants group_id="P3" count="408">Vaccinated toddler dose</participants>
                <participants group_id="P4" count="208">Vaccinated toddler dose</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="408"/>
                <participants group_id="P2" count="391"/>
                <participants group_id="P3" count="404"/>
                <participants group_id="P4" count="200"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed to return</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Parent or legal guardian request</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>13vPnC (Pilot Lot 1)</title>
          <description>Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1 at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.</description>
        </group>
        <group group_id="B2">
          <title>13vPnC (Pilot Lot 2)</title>
          <description>Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 2 at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.</description>
        </group>
        <group group_id="B3">
          <title>13vPnC (Manufacturing Lot)</title>
          <description>Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) manufacturing lot (manu lot) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.</description>
        </group>
        <group group_id="B4">
          <title>7vPnC</title>
          <description>Participants received 1 single 0.5 milliliter (mL) dose of 7-valent pneumococcal conjugate vaccine (7vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="489"/>
            <count group_id="B2" value="488"/>
            <count group_id="B3" value="489"/>
            <count group_id="B4" value="246"/>
            <count group_id="B5" value="1712"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.2" spread="0.3"/>
                    <measurement group_id="B2" value="2.2" spread="0.3"/>
                    <measurement group_id="B3" value="2.2" spread="0.3"/>
                    <measurement group_id="B4" value="2.2" spread="0.3"/>
                    <measurement group_id="B5" value="2.2" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="230"/>
                    <measurement group_id="B2" value="226"/>
                    <measurement group_id="B3" value="213"/>
                    <measurement group_id="B4" value="115"/>
                    <measurement group_id="B5" value="784"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="259"/>
                    <measurement group_id="B2" value="260"/>
                    <measurement group_id="B3" value="275"/>
                    <measurement group_id="B4" value="131"/>
                    <measurement group_id="B5" value="925"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in the Three 13vPnC Groups 1 Month After the Infant Series</title>
        <description>Antibody geometric mean concentration (GMC) as measured by micrograms per milliliter (mcg/mL) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.</description>
        <time_frame>1 Month after the infant series (7 Months of age)</time_frame>
        <population>Evaluable immunogenicity population: treatments as randomized at all expected doses, blood drawn within specified timeframes, at least 1 valid and determinate assay result for proposed analysis, and no major protocol violations; (n)=number of participants with IgG antibody concentration to given serotype for the three 13vPnC lots, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC (Pilot Lot 1)</title>
            <description>Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1 at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC (Pilot Lot 2)</title>
            <description>Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 2 at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>13vPnC (Manufacturing Lot)</title>
            <description>Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) manufacturing lot (manu lot) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in the Three 13vPnC Groups 1 Month After the Infant Series</title>
          <description>Antibody geometric mean concentration (GMC) as measured by micrograms per milliliter (mcg/mL) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.</description>
          <population>Evaluable immunogenicity population: treatments as randomized at all expected doses, blood drawn within specified timeframes, at least 1 valid and determinate assay result for proposed analysis, and no major protocol violations; (n)=number of participants with IgG antibody concentration to given serotype for the three 13vPnC lots, respectively.</population>
          <units>GMC mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="427"/>
                <count group_id="O3" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common serotypes - serotype 4 (n=411, 404, 398)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" lower_limit="1.24" upper_limit="1.43"/>
                    <measurement group_id="O2" value="1.34" lower_limit="1.25" upper_limit="1.44"/>
                    <measurement group_id="O3" value="1.75" lower_limit="1.63" upper_limit="1.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 6B (n=409, 401, 396)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.89" lower_limit="2.58" upper_limit="3.23"/>
                    <measurement group_id="O2" value="2.15" lower_limit="1.91" upper_limit="2.42"/>
                    <measurement group_id="O3" value="2.54" lower_limit="2.27" upper_limit="2.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 9V (n=411, 403, 396)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" lower_limit="0.98" upper_limit="1.12"/>
                    <measurement group_id="O2" value="1.11" lower_limit="1.04" upper_limit="1.19"/>
                    <measurement group_id="O3" value="1.11" lower_limit="1.04" upper_limit="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 14 (n=398. 387, 387)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.97" lower_limit="4.59" upper_limit="5.37"/>
                    <measurement group_id="O2" value="5.13" lower_limit="4.70" upper_limit="5.59"/>
                    <measurement group_id="O3" value="5.18" lower_limit="4.72" upper_limit="5.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 18C (n=413, 401, 398)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.30" lower_limit="1.22" upper_limit="1.38"/>
                    <measurement group_id="O2" value="1.34" lower_limit="1.24" upper_limit="1.44"/>
                    <measurement group_id="O3" value="1.48" lower_limit="1.38" upper_limit="1.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 19F (n=408, 399, 398)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.85" lower_limit="1.71" upper_limit="1.99"/>
                    <measurement group_id="O2" value="2.07" lower_limit="1.92" upper_limit="2.24"/>
                    <measurement group_id="O3" value="2.59" lower_limit="2.40" upper_limit="2.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 23F (n=411, 402, 399)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.24" lower_limit="1.13" upper_limit="1.36"/>
                    <measurement group_id="O2" value="1.27" lower_limit="1.15" upper_limit="1.40"/>
                    <measurement group_id="O3" value="1.03" lower_limit="0.94" upper_limit="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 1 (n=411, 403,395)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" lower_limit="1.50" upper_limit="1.76"/>
                    <measurement group_id="O2" value="1.81" lower_limit="1.66" upper_limit="1.98"/>
                    <measurement group_id="O3" value="1.91" lower_limit="1.76" upper_limit="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 3 (n=406, 391,393)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" lower_limit="0.48" upper_limit="0.55"/>
                    <measurement group_id="O2" value="0.56" lower_limit="0.52" upper_limit="0.61"/>
                    <measurement group_id="O3" value="0.61" lower_limit="0.57" upper_limit="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 5 (n=412, 402,393)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.35" lower_limit="1.24" upper_limit="1.47"/>
                    <measurement group_id="O2" value="1.05" lower_limit="0.96" upper_limit="1.14"/>
                    <measurement group_id="O3" value="1.35" lower_limit="1.25" upper_limit="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 6A (n=413,402,398)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.40" lower_limit="2.21" upper_limit="2.61"/>
                    <measurement group_id="O2" value="2.10" lower_limit="1.92" upper_limit="2.29"/>
                    <measurement group_id="O3" value="2.12" lower_limit="1.96" upper_limit="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 7F (n=412,401,397)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.54" lower_limit="2.37" upper_limit="2.71"/>
                    <measurement group_id="O2" value="2.52" lower_limit="2.35" upper_limit="2.70"/>
                    <measurement group_id="O3" value="2.67" lower_limit="2.50" upper_limit="2.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 19A (n=411,403,397)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.85" lower_limit="1.71" upper_limit="2.00"/>
                    <measurement group_id="O2" value="2.00" lower_limit="1.85" upper_limit="2.16"/>
                    <measurement group_id="O3" value="1.88" lower_limit="1.74" upper_limit="2.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 4</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 3 lots were considered equivalent if the maximum difference between any 2 lots is less than 0.693 and greater than –0.693 using the equivalence testing procedure for 3 vaccine groups given by Wiens and Iglewicz, for all 13 serotypes.</non_inferiority_desc>
            <param_type>difference in log-transformed GM</param_type>
            <param_value>-0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.11</ci_lower_limit>
            <ci_upper_limit>0.09</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 4</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 3 lots were considered equivalent if the maximum difference between any 2 lots is less than 0.693 and greater than -0.693 using the equivalence testing procedure for 3 vaccine groups given by Wiens and Iglewicz, for all 13 serotypes.</non_inferiority_desc>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.38</ci_lower_limit>
            <ci_upper_limit>-0.17</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 4</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 3 lots were considered equivalent if the maximum difference between any 2 lots is less than 0.693 and greater than -0.693 using the equivalence testing procedure for 3 vaccine groups given by Wiens and Iglewicz, for all 13 serotypes.</non_inferiority_desc>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.37</ci_lower_limit>
            <ci_upper_limit>-0.16</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 6B</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 3 lots were considered equivalent if the maximum difference between any 2 lots is less than 0.693 and greater than -0.693 using the equivalence testing procedure for 3 vaccine groups given by Wiens and Iglewicz, for all 13 serotypes.</non_inferiority_desc>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>0.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.13</ci_lower_limit>
            <ci_upper_limit>0.46</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 6B</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 3 lots were considered equivalent if the maximum difference between any 2 lots is less than 0.693 and greater than -0.693 using the equivalence testing procedure for 3 vaccine groups given by Wiens and Iglewicz, for all 13 serotypes.</non_inferiority_desc>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>0.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.04</ci_lower_limit>
            <ci_upper_limit>0.29</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 6B</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 3 lots were considered equivalent if the maximum difference between any 2 lots is less than 0.693 and greater than -0.693 using the equivalence testing procedure for 3 vaccine groups given by Wiens and Iglewicz, for all 13 serotypes.</non_inferiority_desc>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.33</ci_lower_limit>
            <ci_upper_limit>-0.01</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 9V</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 3 lots were considered equivalent if the maximum difference between any 2 lots is less than 0.693 and greater than -0.693 using the equivalence testing procedure for 3 vaccine groups given by Wiens and Iglewicz, for all 13 serotypes.</non_inferiority_desc>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.16</ci_lower_limit>
            <ci_upper_limit>0.04</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 9V</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 3 lots were considered equivalent if the maximum difference between any 2 lots is less than 0.693 and greater than -0.693 using the equivalence testing procedure for 3 vaccine groups given by Wiens and Iglewicz, for all 13 serotypes.</non_inferiority_desc>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.16</ci_lower_limit>
            <ci_upper_limit>0.04</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 9V</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 3 lots were considered equivalent if the maximum difference between any 2 lots is less than 0.693 and greater than -0.693 using the equivalence testing procedure for 3 vaccine groups given by Wiens and Iglewicz, for all 13 serotypes.</non_inferiority_desc>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.10</ci_lower_limit>
            <ci_upper_limit>0.10</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 14</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 3 lots were considered equivalent if the maximum difference between any 2 lots is less than 0.693 and greater than -0.693 using the equivalence testing procedure for 3 vaccine groups given by Wiens and Iglewicz, for all 13 serotypes.</non_inferiority_desc>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.15</ci_lower_limit>
            <ci_upper_limit>0.09</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 14</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 3 lots were considered equivalent if the maximum difference between any 2 lots is less than 0.693 and greater than -0.693 using the equivalence testing procedure for 3 vaccine groups given by Wiens and Iglewicz, for all 13 serotypes.</non_inferiority_desc>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.16</ci_lower_limit>
            <ci_upper_limit>0.08</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 14</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 3 lots were considered equivalent if the maximum difference between any 2 lots is less than 0.693 and greater than -0.693 using the equivalence testing procedure for 3 vaccine groups given by Wiens and Iglewicz, for all 13 serotypes.</non_inferiority_desc>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.13</ci_lower_limit>
            <ci_upper_limit>0.11</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 18C</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 3 lots were considered equivalent if the maximum difference between any 2 lots is less than 0.693 and greater than -0.693 using the equivalence testing procedure for 3 vaccine groups given by Wiens and Iglewicz, for all 13 serotypes.</non_inferiority_desc>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.13</ci_lower_limit>
            <ci_upper_limit>0.07</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 18C</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 3 lots were considered equivalent if the maximum difference between any 2 lots is less than 0.693 and greater than -0.693 using the equivalence testing procedure for 3 vaccine groups given by Wiens and Iglewicz, for all 13 serotypes.</non_inferiority_desc>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.23</ci_lower_limit>
            <ci_upper_limit>-0.03</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 18C</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 3 lots were considered equivalent if the maximum difference between any 2 lots is less than 0.693 and greater than -0.693 using the equivalence testing procedure for 3 vaccine groups given by Wiens and Iglewicz, for all 13 serotypes.</non_inferiority_desc>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.20</ci_lower_limit>
            <ci_upper_limit>-0.00</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 19F</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 3 lots were considered equivalent if the maximum difference between any 2 lots is less than 0.693 and greater than -0.693 using the equivalence testing procedure for 3 vaccine groups given by Wiens and Iglewicz, for all 13 serotypes.</non_inferiority_desc>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.22</ci_lower_limit>
            <ci_upper_limit>-0.01</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 19F</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 3 lots were considered equivalent if the maximum difference between any 2 lots is less than 0.693 and greater than -0.693 using the equivalence testing procedure for 3 vaccine groups given by Wiens and Iglewicz, for all 13 serotypes.</non_inferiority_desc>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.44</ci_lower_limit>
            <ci_upper_limit>-0.23</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 19F</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 3 lots were considered equivalent if the maximum difference between any 2 lots is less than 0.693 and greater than -0.693 using the equivalence testing procedure for 3 vaccine groups given by Wiens and Iglewicz, for all 13 serotypes.</non_inferiority_desc>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.33</ci_lower_limit>
            <ci_upper_limit>-0.11</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 23F</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 3 lots were considered equivalent if the maximum difference between any 2 lots is less than 0.693 and greater than -0.693 using the equivalence testing procedure for 3 vaccine groups given by Wiens and Iglewicz, for all 13 serotypes.</non_inferiority_desc>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.16</ci_lower_limit>
            <ci_upper_limit>0.11</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 23F</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 3 lots were considered equivalent if the maximum difference between any 2 lots is less than 0.693 and greater than -0.693 using the equivalence testing procedure for 3 vaccine groups given by Wiens and Iglewicz, for all 13 serotypes.</non_inferiority_desc>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>0.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.04</ci_lower_limit>
            <ci_upper_limit>0.31</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 23F</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 3 lots were considered equivalent if the maximum difference between any 2 lots is less than 0.693 and greater than -0.693 using the equivalence testing procedure for 3 vaccine groups given by Wiens and Iglewicz, for all 13 serotypes.</non_inferiority_desc>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>0.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.07</ci_lower_limit>
            <ci_upper_limit>0.34</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 1</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 3 lots were considered equivalent if the maximum difference between any 2 lots is less than 0.693 and greater than -0.693 using the equivalence testing procedure for 3 vaccine groups given by Wiens and Iglewicz, for all 13 serotypes.</non_inferiority_desc>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.23</ci_lower_limit>
            <ci_upper_limit>0.01</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 1</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 3 lots were considered equivalent if the maximum difference between any 2 lots is less than 0.693 and greater than -0.693 using the equivalence testing procedure for 3 vaccine groups given by Wiens and Iglewicz, for all 13 serotypes.</non_inferiority_desc>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.28</ci_lower_limit>
            <ci_upper_limit>-0.04</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 1</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 3 lots were considered equivalent if the maximum difference between any 2 lots is less than 0.693 and greater than -0.693 using the equivalence testing procedure for 3 vaccine groups given by Wiens and Iglewicz, for all 13 serotypes.</non_inferiority_desc>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.17</ci_lower_limit>
            <ci_upper_limit>0.06</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 3</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 3 lots were considered equivalent if the maximum difference between any 2 lots is less than 0.693 and greater than -0.693 using the equivalence testing procedure for 3 vaccine groups given by Wiens and Iglewicz, for all 13 serotypes.</non_inferiority_desc>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.19</ci_lower_limit>
            <ci_upper_limit>0.02</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 3</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 3 lots were considered equivalent if the maximum difference between any 2 lots is less than 0.693 and greater than -0.693 using the equivalence testing procedure for 3 vaccine groups given by Wiens and Iglewicz, for all 13 serotypes.</non_inferiority_desc>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.28</ci_lower_limit>
            <ci_upper_limit>-0.07</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 3</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 3 lots were considered equivalent if the maximum difference between any 2 lots is less than 0.693 and greater than -0.693 using the equivalence testing procedure for 3 vaccine groups given by Wiens and Iglewicz, for all 13 serotypes.</non_inferiority_desc>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.19</ci_lower_limit>
            <ci_upper_limit>0.02</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 5</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 3 lots were considered equivalent if the maximum difference between any 2 lots is less than 0.693 and greater than -0.693 using the equivalence testing procedure for 3 vaccine groups given by Wiens and Iglewicz, for all 13 serotypes.</non_inferiority_desc>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>0.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.13</ci_lower_limit>
            <ci_upper_limit>0.37</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 5</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 3 lots were considered equivalent if the maximum difference between any 2 lots is less than 0.693 and greater than -0.693 using the equivalence testing procedure for 3 vaccine groups given by Wiens and Iglewicz, for all 13 serotypes.</non_inferiority_desc>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.12</ci_lower_limit>
            <ci_upper_limit>0.12</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 5</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 3 lots were considered equivalent if the maximum difference between any 2 lots is less than 0.693 and greater than -0.693 using the equivalence testing procedure for 3 vaccine groups given by Wiens and Iglewicz, for all 13 serotypes.</non_inferiority_desc>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.37</ci_lower_limit>
            <ci_upper_limit>-0.13</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 6A</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 3 lots were considered equivalent if the maximum difference between any 2 lots is less than 0.693 and greater than -0.693 using the equivalence testing procedure for 3 vaccine groups given by Wiens and Iglewicz, for all 13 serotypes.</non_inferiority_desc>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>0.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.02</ci_lower_limit>
            <ci_upper_limit>0.25</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 6A</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 3 lots were considered equivalent if the maximum difference between any 2 lots is less than 0.693 and greater than -0.693 using the equivalence testing procedure for 3 vaccine groups given by Wiens and Iglewicz, for all 13 serotypes.</non_inferiority_desc>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>0.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.01</ci_lower_limit>
            <ci_upper_limit>0.24</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 6A</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 3 lots were considered equivalent if the maximum difference between any 2 lots is less than 0.693 and greater than -0.693 using the equivalence testing procedure for 3 vaccine groups given by Wiens and Iglewicz, for all 13 serotypes.</non_inferiority_desc>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.13</ci_lower_limit>
            <ci_upper_limit>0.11</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 7F</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 3 lots were considered equivalent if the maximum difference between any 2 lots is less than 0.693 and greater than -0.693 using the equivalence testing procedure for 3 vaccine groups given by Wiens and Iglewicz, for all 13 serotypes.</non_inferiority_desc>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.09</ci_lower_limit>
            <ci_upper_limit>0.10</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 7F</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 3 lots were considered equivalent if the maximum difference between any 2 lots is less than 0.693 and greater than -0.693 using the equivalence testing procedure for 3 vaccine groups given by Wiens and Iglewicz, for all 13 serotypes.</non_inferiority_desc>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.14</ci_lower_limit>
            <ci_upper_limit>0.04</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 7F</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 3 lots were considered equivalent if the maximum difference between any 2 lots is less than 0.693 and greater than -0.693 using the equivalence testing procedure for 3 vaccine groups given by Wiens and Iglewicz, for all 13 serotypes.</non_inferiority_desc>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.15</ci_lower_limit>
            <ci_upper_limit>0.04</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 19A</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 3 lots were considered equivalent if the maximum difference between any 2 lots is less than 0.693 and greater than -0.693 using the equivalence testing procedure for 3 vaccine groups given by Wiens and Iglewicz, for all 13 serotypes.</non_inferiority_desc>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.19</ci_lower_limit>
            <ci_upper_limit>0.03</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 19A</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 3 lots were considered equivalent if the maximum difference between any 2 lots is less than 0.693 and greater than -0.693 using the equivalence testing procedure for 3 vaccine groups given by Wiens and Iglewicz, for all 13 serotypes.</non_inferiority_desc>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.12</ci_lower_limit>
            <ci_upper_limit>0.09</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 19A</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 3 lots were considered equivalent if the maximum difference between any 2 lots is less than 0.693 and greater than -0.693 using the equivalence testing procedure for 3 vaccine groups given by Wiens and Iglewicz, for all 13 serotypes.</non_inferiority_desc>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>0.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.05</ci_lower_limit>
            <ci_upper_limit>0.17</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Predefined Antibody Level ≥0.1 International Units Per Milliliter (IU/mL) for Tetanus Toxoid in the Combined 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series</title>
        <description>Percentage of participants achieving predefined antibody threshold ≥0.1 IU/ mL along with the corresponding 95% CI for concomitant antigen tetanus toxoid are presented. Exact 2-sided CI was based on the observed proportion of participants. Combined 13vPnC group includes participants randomized to pilot lot 1, pilot lot 2, or the manufacturing lot.</description>
        <time_frame>1 month after the infant series (7 months of age)</time_frame>
        <population>Evaluable immunogenicity population. Combined 13vPnC group includes participants who received pilot lot 1, pilot lot 2, or manufacturing lot; N=number of participants analyzed with a determinate post-third dose IgG antibody concentration to the given concomitant vaccine component.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined 13vPnC</title>
            <description>Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1 or 2, or manufacturing lot at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>Participants received 1 single 0.5 milliliter (mL) dose of 7-valent pneumococcal conjugate vaccine (7vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Predefined Antibody Level ≥0.1 International Units Per Milliliter (IU/mL) for Tetanus Toxoid in the Combined 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series</title>
          <description>Percentage of participants achieving predefined antibody threshold ≥0.1 IU/ mL along with the corresponding 95% CI for concomitant antigen tetanus toxoid are presented. Exact 2-sided CI was based on the observed proportion of participants. Combined 13vPnC group includes participants randomized to pilot lot 1, pilot lot 2, or the manufacturing lot.</description>
          <population>Evaluable immunogenicity population. Combined 13vPnC group includes participants who received pilot lot 1, pilot lot 2, or manufacturing lot; N=number of participants analyzed with a determinate post-third dose IgG antibody concentration to the given concomitant vaccine component.</population>
          <units>observed percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.4" lower_limit="95.3" upper_limit="99.7"/>
                    <measurement group_id="O2" value="98.5" lower_limit="95.6" upper_limit="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tetanus toxoid: Difference in proportions (combined 13vPnC, 7vPnC) expressed as a percentage.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For each of the 5 concomitant antigens (tetanus toxoid, poliovirus Type 1, 2, and 3, and hepatitis b antibodies), non-inferiority was shown if the lower limit of the 2-sided 95% CI, computed using the Chan and Zhang procedure for the difference in proportions, is greater than -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.3</ci_lower_limit>
            <ci_upper_limit>3.0</ci_upper_limit>
            <estimate_desc>Exact 2-sided CI for difference in proportions (combined 13vPnC, 7vPnC) expressed as a percentage.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Predefined Antibody Level ≥1:8 for Poliovirus in the Combined 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series</title>
        <description>Percentage of participants achieving predefined antibody threshold ≥1:8 along with the corresponding 95% CI for concomitant antigen poliovirus type 1, type 2, and type 3 (Sabin strains 1, 2, 3) are presented. Exact 2-sided CI was based on the observed proportion of participants. Combined 13vPnC group includes participants randomized to pilot lot 1, pilot lot 2, or the manufacturing lot.</description>
        <time_frame>1 month after the infant series (7 months of age)</time_frame>
        <population>Evaluable immunogenicity population; N=number of participants analyzed with a determinate post-third dose IgG antibody concentration to the given concomitant vaccine component; n)=number of participants with an antibody titer ≥ prespecified level for given concomitant vaccine antigen for combined 13vPnC and 7vPnC, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined 13vPnC</title>
            <description>Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1 or 2, or manufacturing lot at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>Participants received 1 single 0.5 milliliter (mL) dose of 7-valent pneumococcal conjugate vaccine (7vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Predefined Antibody Level ≥1:8 for Poliovirus in the Combined 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series</title>
          <description>Percentage of participants achieving predefined antibody threshold ≥1:8 along with the corresponding 95% CI for concomitant antigen poliovirus type 1, type 2, and type 3 (Sabin strains 1, 2, 3) are presented. Exact 2-sided CI was based on the observed proportion of participants. Combined 13vPnC group includes participants randomized to pilot lot 1, pilot lot 2, or the manufacturing lot.</description>
          <population>Evaluable immunogenicity population; N=number of participants analyzed with a determinate post-third dose IgG antibody concentration to the given concomitant vaccine component; n)=number of participants with an antibody titer ≥ prespecified level for given concomitant vaccine antigen for combined 13vPnC and 7vPnC, respectively.</population>
          <units>observed percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="187"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Poliovirus type 1 (n=183, 187)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.0" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poliovirus type 2 (n=181, 186)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.9" lower_limit="96.1" upper_limit="99.9"/>
                    <measurement group_id="O2" value="99.5" lower_limit="97.1" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poliovirus type 3 (n=182, 186)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.0" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.5" lower_limit="97.1" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Poliovirus type 1: Difference in proportions (combined 13vPnC, 7vPnC) expressed as a percentage.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For each of the 5 concomitant antigens (tetanus toxoid, poliovirus Type 1, 2, and 3, and hepatitis b antibodies), non-inferiority was shown if the lower limit of the 2-sided 95% CI, computed using the Chan and Zhang procedure for the difference in proportions, is greater than -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.1</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
            <estimate_desc>Exact 2-sided CI for difference in proportions (combined 13vPnC, 7vPnC) expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Poliovirus type 2: Difference in proportions (combined 13vPnC, 7vPnC) expressed as a percentage.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For each of the 5 concomitant antigens (tetanus toxoid, poliovirus Type 1, 2, and 3, and hepatitis b antibodies), non-inferiority was shown if the lower limit of the 2-sided 95% CI, computed using the Chan and Zhang procedure for the difference in proportions, is greater than -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.4</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
            <estimate_desc>Exact 2-sided CI for difference in proportions (combined 13vPnC, 7vPnC) expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Poliovirus type 3: Difference in proportions (combined 13vPnC, 7vPnC) expressed as a percentage.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For each of the 5 concomitant antigens (tetanus toxoid, poliovirus Type 1, 2, and 3, and hepatitis b antibodies), non-inferiority was shown if the lower limit of the 2-sided 95% CI, computed using the Chan and Zhang procedure for the difference in proportions, is greater than -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.5</ci_lower_limit>
            <ci_upper_limit>3.0</ci_upper_limit>
            <estimate_desc>Exact 2-sided CI for difference in proportions (combined 13vPnC, 7vPnC) expressed as a percentage.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Predefined Antibody Level ≥10.0 Milli-International Units Per Milliliter (mIU/mL) for Hepatitis B in the Combined 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series</title>
        <description>Percentage of participants achieving predefined antibody threshold ≥10.0 mIU/ mL along with the corresponding 95% CI for concomitant antigen hepatitis B are presented. Exact 2-sided CI was based on the observed proportion of participants. Combined 13vPnC group includes participants randomized to pilot lot 1, pilot lot 2, or the manufacturing lot.</description>
        <time_frame>1 month after the infant series (7 months of age)</time_frame>
        <population>Evaluable immunogenicity population; N=number of participants analyzed with a determinate post-third dose IgG antibody concentration to the given concomitant vaccine component.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined 13vPnC</title>
            <description>Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1 or 2, or manufacturing lot at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>Participants received 1 single 0.5 milliliter (mL) dose of 7-valent pneumococcal conjugate vaccine (7vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Predefined Antibody Level ≥10.0 Milli-International Units Per Milliliter (mIU/mL) for Hepatitis B in the Combined 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series</title>
          <description>Percentage of participants achieving predefined antibody threshold ≥10.0 mIU/ mL along with the corresponding 95% CI for concomitant antigen hepatitis B are presented. Exact 2-sided CI was based on the observed proportion of participants. Combined 13vPnC group includes participants randomized to pilot lot 1, pilot lot 2, or the manufacturing lot.</description>
          <population>Evaluable immunogenicity population; N=number of participants analyzed with a determinate post-third dose IgG antibody concentration to the given concomitant vaccine component.</population>
          <units>observed percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.6" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="97.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hepatitis B: Difference in proportions (combined 13vPnC, 7vPnC) expressed as a percentage.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For each of the 5 concomitant antigens (tetanus toxoid, poliovirus Type 1, 2, and 3, and hepatitis b antibodies), non-inferiority was shown if the lower limit of the 2-sided 95% CI, computed using the Chan and Zhang procedure for the difference in proportions, is greater than -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>2.2</ci_upper_limit>
            <estimate_desc>Exact 2-sided CI for difference in proportions (combined 13vPnC, 7vPnC) expressed as a percentage.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.35 Mcg/mL in the Three 13vPnC Groups 1 Month After the Infant Series</title>
        <description>Percentage of participants achieving predefined antibody threshold ≥0.35mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.</description>
        <time_frame>1 month after the infant series (7 months of age)</time_frame>
        <population>Evaluable immunogenicity population; (n)=number of subjects with a determinate IgG antibody concentration to the given serotype for the three 13vPnC lots, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC (Pilot Lot 1)</title>
            <description>Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1 at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC (Pilot Lot 2)</title>
            <description>Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 2 at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>13vPnC (Manufacturing Lot)</title>
            <description>Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) manufacturing lot (manu lot) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.35 Mcg/mL in the Three 13vPnC Groups 1 Month After the Infant Series</title>
          <description>Percentage of participants achieving predefined antibody threshold ≥0.35mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.</description>
          <population>Evaluable immunogenicity population; (n)=number of subjects with a determinate IgG antibody concentration to the given serotype for the three 13vPnC lots, respectively.</population>
          <units>observed percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
                <count group_id="O2" value="427"/>
                <count group_id="O3" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common serotypes - serotype 4 (n=411, 404, 398)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.6" lower_limit="95.6" upper_limit="98.8"/>
                    <measurement group_id="O2" value="95.5" lower_limit="93.0" upper_limit="97.3"/>
                    <measurement group_id="O3" value="98.5" lower_limit="96.7" upper_limit="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 6B (n=409, 401, 396)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.9" lower_limit="92.3" upper_limit="96.8"/>
                    <measurement group_id="O2" value="89.5" lower_limit="86.1" upper_limit="92.3"/>
                    <measurement group_id="O3" value="94.4" lower_limit="91.7" upper_limit="96.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 9V (n=411, 403, 396)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.4" lower_limit="92.9" upper_limit="97.2"/>
                    <measurement group_id="O2" value="95.5" lower_limit="93.0" upper_limit="97.3"/>
                    <measurement group_id="O3" value="96.5" lower_limit="94.1" upper_limit="98.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 14 (n=398, 387, 387)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.2" lower_limit="97.8" upper_limit="99.8"/>
                    <measurement group_id="O2" value="99.0" lower_limit="97.4" upper_limit="99.7"/>
                    <measurement group_id="O3" value="98.2" lower_limit="96.3" upper_limit="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 18C (n=413, 401, 398)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.8" lower_limit="95.9" upper_limit="99.0"/>
                    <measurement group_id="O2" value="95.8" lower_limit="93.3" upper_limit="97.5"/>
                    <measurement group_id="O3" value="98.0" lower_limit="96.1" upper_limit="99.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 19F (n=408, 399, 398)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.8" lower_limit="95.9" upper_limit="99.0"/>
                    <measurement group_id="O2" value="97.5" lower_limit="95.4" upper_limit="98.8"/>
                    <measurement group_id="O3" value="99.2" lower_limit="97.8" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 23F (n=411, 402, 399)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.2" lower_limit="88.1" upper_limit="93.8"/>
                    <measurement group_id="O2" value="88.1" lower_limit="84.5" upper_limit="91.1"/>
                    <measurement group_id="O3" value="87.2" lower_limit="83.5" upper_limit="90.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 1 (n=411, 403,395)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.8" lower_limit="95.9" upper_limit="99.0"/>
                    <measurement group_id="O2" value="97.0" lower_limit="94.9" upper_limit="98.5"/>
                    <measurement group_id="O3" value="98.5" lower_limit="96.7" upper_limit="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 3 (n=406, 391,393)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.5" lower_limit="63.7" upper_limit="73.0"/>
                    <measurement group_id="O2" value="72.4" lower_limit="67.7" upper_limit="76.8"/>
                    <measurement group_id="O3" value="79.1" lower_limit="74.8" upper_limit="83.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 5 (n=412, 402,393)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.2" lower_limit="91.5" upper_limit="96.2"/>
                    <measurement group_id="O2" value="90.3" lower_limit="87.0" upper_limit="93.0"/>
                    <measurement group_id="O3" value="94.4" lower_limit="91.6" upper_limit="96.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 6A (n=413,402,398)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.1" lower_limit="96.2" upper_limit="99.2"/>
                    <measurement group_id="O2" value="95.5" lower_limit="93.0" upper_limit="97.3"/>
                    <measurement group_id="O3" value="98.2" lower_limit="96.4" upper_limit="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 7F (n=412,401,397)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.8" lower_limit="98.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.0" lower_limit="97.5" upper_limit="99.7"/>
                    <measurement group_id="O3" value="99.7" lower_limit="98.6" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 19A (n=411,403,397)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.1" lower_limit="96.2" upper_limit="99.2"/>
                    <measurement group_id="O2" value="99.0" lower_limit="97.5" upper_limit="99.7"/>
                    <measurement group_id="O3" value="98.7" lower_limit="97.1" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 4</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Exact, unconditional 2-sided 95% CI on the pairwise difference in proportions were computed using the noninferiority procedure of Chan and Zhang, using the standardized test statistics and gamma=0.000001.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>2.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.51</ci_lower_limit>
            <ci_upper_limit>4.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 4</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Exact, unconditional 2-sided 95% CI on the pairwise difference in proportions were computed using the noninferiority procedure of Chan and Zhang, using the standardized test statistics and gamma=0.000001.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.09</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 4</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Exact, unconditional 2-sided 95% CI on the pairwise difference in proportions were computed using the noninferiority procedure of Chan and Zhang, using the standardized test statistics and gamma=0.000001.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-2.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.58</ci_lower_limit>
            <ci_upper_limit>-0.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 6B</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Exact, unconditional 2-sided 95% CI on the pairwise difference in proportions were computed using the noninferiority procedure of Chan and Zhang, using the standardized test statistics and gamma=0.000001.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>5.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.55</ci_lower_limit>
            <ci_upper_limit>9.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 6B</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Exact, unconditional 2-sided 95% CI on the pairwise difference in proportions were computed using the noninferiority procedure of Chan and Zhang, using the standardized test statistics and gamma=0.000001.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.77</ci_lower_limit>
            <ci_upper_limit>3.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 6B</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Exact, unconditional 2-sided 95% CI on the pairwise difference in proportions were computed using the noninferiority procedure of Chan and Zhang, using the standardized test statistics and gamma=0.000001.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-4.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.82</ci_lower_limit>
            <ci_upper_limit>-1.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 9V</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Exact, unconditional 2-sided 95% CI on the pairwise difference in proportions were computed using the noninferiority procedure of Chan and Zhang, using the standardized test statistics and gamma=0.000001.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.13</ci_lower_limit>
            <ci_upper_limit>2.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 9V</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Exact, unconditional 2-sided 95% CI on the pairwise difference in proportions were computed using the noninferiority procedure of Chan and Zhang, using the standardized test statistics and gamma=0.000001.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.97</ci_lower_limit>
            <ci_upper_limit>1.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 9V</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Exact, unconditional 2-sided 95% CI on the pairwise difference in proportions were computed using the noninferiority procedure of Chan and Zhang, using the standardized test statistics and gamma=0.000001.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.81</ci_lower_limit>
            <ci_upper_limit>1.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 14</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Exact, unconditional 2-sided 95% CI on the pairwise difference in proportions were computed using the noninferiority procedure of Chan and Zhang, using the standardized test statistics and gamma=0.000001.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.27</ci_lower_limit>
            <ci_upper_limit>1.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 14</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Exact, unconditional 2-sided 95% CI on the pairwise difference in proportions were computed using the noninferiority procedure of Chan and Zhang, using the standardized test statistics and gamma=0.000001.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.60</ci_lower_limit>
            <ci_upper_limit>3.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 14</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Exact, unconditional 2-sided 95% CI on the pairwise difference in proportions were computed using the noninferiority procedure of Chan and Zhang, using the standardized test statistics and gamma=0.000001.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.04</ci_lower_limit>
            <ci_upper_limit>2.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 18C</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Exact, unconditional 2-sided 95% CI on the pairwise difference in proportions were computed using the noninferiority procedure of Chan and Zhang, using the standardized test statistics and gamma=0.000001.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.38</ci_lower_limit>
            <ci_upper_limit>4.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 18C</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Exact, unconditional 2-sided 95% CI on the pairwise difference in proportions were computed using the noninferiority procedure of Chan and Zhang, using the standardized test statistics and gamma=0.000001.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.33</ci_lower_limit>
            <ci_upper_limit>1.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 18C</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Exact, unconditional 2-sided 95% CI on the pairwise difference in proportions were computed using the noninferiority procedure of Chan and Zhang, using the standardized test statistics and gamma=0.000001.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.89</ci_lower_limit>
            <ci_upper_limit>0.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 19F</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Exact, unconditional 2-sided 95% CI on the pairwise difference in proportions were computed using the noninferiority procedure of Chan and Zhang, using the standardized test statistics and gamma=0.000001.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.93</ci_lower_limit>
            <ci_upper_limit>2.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 19F</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Exact, unconditional 2-sided 95% CI on the pairwise difference in proportions were computed using the noninferiority procedure of Chan and Zhang, using the standardized test statistics and gamma=0.000001.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.46</ci_lower_limit>
            <ci_upper_limit>0.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 19F</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Exact, unconditional 2-sided 95% CI on the pairwise difference in proportions were computed using the noninferiority procedure of Chan and Zhang, using the standardized test statistics and gamma=0.000001.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.87</ci_lower_limit>
            <ci_upper_limit>0.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 23F</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Exact, unconditional 2-sided 95% CI on the pairwise difference in proportions were computed using the noninferiority procedure of Chan and Zhang, using the standardized test statistics and gamma=0.000001.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>3.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.03</ci_lower_limit>
            <ci_upper_limit>7.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 23F</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Exact, unconditional 2-sided 95% CI on the pairwise difference in proportions were computed using the noninferiority procedure of Chan and Zhang, using the standardized test statistics and gamma=0.000001.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>4.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.27</ci_lower_limit>
            <ci_upper_limit>8.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 23F</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Exact, unconditional 2-sided 95% CI on the pairwise difference in proportions were computed using the noninferiority procedure of Chan and Zhang, using the standardized test statistics and gamma=0.000001.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.75</ci_lower_limit>
            <ci_upper_limit>5.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 1</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Exact, unconditional 2-sided 95% CI on the pairwise difference in proportions were computed using the noninferiority procedure of Chan and Zhang, using the standardized test statistics and gamma=0.000001.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.48</ci_lower_limit>
            <ci_upper_limit>3.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 1</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Exact, unconditional 2-sided 95% CI on the pairwise difference in proportions were computed using the noninferiority procedure of Chan and Zhang, using the standardized test statistics and gamma=0.000001.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.78</ci_lower_limit>
            <ci_upper_limit>1.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 1</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Exact, unconditional 2-sided 95% CI on the pairwise difference in proportions were computed using the noninferiority procedure of Chan and Zhang, using the standardized test statistics and gamma=0.000001.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.77</ci_lower_limit>
            <ci_upper_limit>0.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 3</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Exact, unconditional 2-sided 95% CI on the pairwise difference in proportions were computed using the noninferiority procedure of Chan and Zhang, using the standardized test statistics and gamma=0.000001.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-3.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.27</ci_lower_limit>
            <ci_upper_limit>2.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 3</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Exact, unconditional 2-sided 95% CI on the pairwise difference in proportions were computed using the noninferiority procedure of Chan and Zhang, using the standardized test statistics and gamma=0.000001.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-10.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.80</ci_lower_limit>
            <ci_upper_limit>-4.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 3</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Exact, unconditional 2-sided 95% CI on the pairwise difference in proportions were computed using the noninferiority procedure of Chan and Zhang, using the standardized test statistics and gamma=0.000001.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-6.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.76</ci_lower_limit>
            <ci_upper_limit>-0.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 5</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Exact, unconditional 2-sided 95% CI on the pairwise difference in proportions were computed using the noninferiority procedure of Chan and Zhang, using the standardized test statistics and gamma=0.000001.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>3.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.15</ci_lower_limit>
            <ci_upper_limit>7.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 5</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Exact, unconditional 2-sided 95% CI on the pairwise difference in proportions were computed using the noninferiority procedure of Chan and Zhang, using the standardized test statistics and gamma=0.000001.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.52</ci_lower_limit>
            <ci_upper_limit>3.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 5</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Exact, unconditional 2-sided 95% CI on the pairwise difference in proportions were computed using the noninferiority procedure of Chan and Zhang, using the standardized test statistics and gamma=0.000001.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-4.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.92</ci_lower_limit>
            <ci_upper_limit>-0.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 6A</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Exact, unconditional 2-sided 95% CI on the pairwise difference in proportions were computed using the noninferiority procedure of Chan and Zhang, using the standardized test statistics and gamma=0.000001.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>2.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.12</ci_lower_limit>
            <ci_upper_limit>5.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 6A</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Exact, unconditional 2-sided 95% CI on the pairwise difference in proportions were computed using the noninferiority procedure of Chan and Zhang, using the standardized test statistics and gamma=0.000001.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.22</ci_lower_limit>
            <ci_upper_limit>1.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 6A</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Exact, unconditional 2-sided 95% CI on the pairwise difference in proportions were computed using the noninferiority procedure of Chan and Zhang, using the standardized test statistics and gamma=0.000001.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-2.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.39</ci_lower_limit>
            <ci_upper_limit>-0.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 7F</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Exact, unconditional 2-sided 95% CI on the pairwise difference in proportions were computed using the noninferiority procedure of Chan and Zhang, using the standardized test statistics and gamma=0.000001.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.47</ci_lower_limit>
            <ci_upper_limit>2.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 7F</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Exact, unconditional 2-sided 95% CI on the pairwise difference in proportions were computed using the noninferiority procedure of Chan and Zhang, using the standardized test statistics and gamma=0.000001.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.12</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 7F</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Exact, unconditional 2-sided 95% CI on the pairwise difference in proportions were computed using the noninferiority procedure of Chan and Zhang, using the standardized test statistics and gamma=0.000001.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.30</ci_lower_limit>
            <ci_upper_limit>0.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 19A</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Exact, unconditional 2-sided 95% CI on the pairwise difference in proportions were computed using the noninferiority procedure of Chan and Zhang, using the standardized test statistics and gamma=0.000001.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.91</ci_lower_limit>
            <ci_upper_limit>0.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 19A</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Exact, unconditional 2-sided 95% CI on the pairwise difference in proportions were computed using the noninferiority procedure of Chan and Zhang, using the standardized test statistics and gamma=0.000001.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.69</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 19A</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Exact, unconditional 2-sided 95% CI on the pairwise difference in proportions were computed using the noninferiority procedure of Chan and Zhang, using the standardized test statistics and gamma=0.000001.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.40</ci_lower_limit>
            <ci_upper_limit>2.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.35 Mcg/mL in the Three 13vPnC Groups 1 Month After the Toddler Dose</title>
        <description>Percentage of participants achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.</description>
        <time_frame>1 month after the toddler dose (13 months of age)</time_frame>
        <population>Evaluable immunogenicity population; (n)=number of subjects with a determinate IgG antibody concentration to the given serotype for the three 13vPnC lots, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC (Pilot Lot 1)</title>
            <description>Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1 at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC (Pilot Lot 2)</title>
            <description>Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 2 at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>13vPnC (Manufacturing Lot)</title>
            <description>Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) manufacturing lot (manu lot) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.35 Mcg/mL in the Three 13vPnC Groups 1 Month After the Toddler Dose</title>
          <description>Percentage of participants achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.</description>
          <population>Evaluable immunogenicity population; (n)=number of subjects with a determinate IgG antibody concentration to the given serotype for the three 13vPnC lots, respectively.</population>
          <units>observed percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="415"/>
                <count group_id="O2" value="397"/>
                <count group_id="O3" value="408"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common serotypes - serotype 4 (n=364, 342, 355)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.2" lower_limit="97.6" upper_limit="99.8"/>
                    <measurement group_id="O2" value="99.1" lower_limit="97.5" upper_limit="99.8"/>
                    <measurement group_id="O3" value="100.0" lower_limit="99.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 6B (n=368,341,357)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="99.0" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.9" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="99.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 9V (n=368,342,357)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.7" lower_limit="98.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.7" lower_limit="98.4" upper_limit="100.0"/>
                    <measurement group_id="O3" value="99.2" lower_limit="97.6" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 14 (n=366,344,358)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="99.0" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.7" lower_limit="98.4" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="99.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 18C (n=362,341,354)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.9" lower_limit="97.2" upper_limit="99.7"/>
                    <measurement group_id="O2" value="98.5" lower_limit="96.6" upper_limit="99.5"/>
                    <measurement group_id="O3" value="99.4" lower_limit="98.0" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 19F (n=362,342,353)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.3" lower_limit="96.4" upper_limit="99.4"/>
                    <measurement group_id="O2" value="98.8" lower_limit="97.0" upper_limit="99.7"/>
                    <measurement group_id="O3" value="99.4" lower_limit="98.0" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 23F (n=362,340,353)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.4" lower_limit="98.0" upper_limit="99.9"/>
                    <measurement group_id="O2" value="99.1" lower_limit="97.4" upper_limit="99.8"/>
                    <measurement group_id="O3" value="98.3" lower_limit="96.3" upper_limit="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 1 (n=367,344,357)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="99.0" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.1" lower_limit="97.5" upper_limit="99.8"/>
                    <measurement group_id="O3" value="99.2" lower_limit="97.6" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 3 (n=366,343,356)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.6" lower_limit="79.4" upper_limit="87.3"/>
                    <measurement group_id="O2" value="80.8" lower_limit="76.2" upper_limit="84.8"/>
                    <measurement group_id="O3" value="88.5" lower_limit="84.7" upper_limit="91.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 5 (n=368,343,357)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.7" lower_limit="98.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.4" lower_limit="97.9" upper_limit="99.9"/>
                    <measurement group_id="O3" value="99.7" lower_limit="98.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 6A (n=366,342,355)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="99.0" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.9" upper_limit="100.0"/>
                    <measurement group_id="O3" value="99.7" lower_limit="98.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 7F (n=366,343,358)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="99.0" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.4" lower_limit="97.9" upper_limit="99.9"/>
                    <measurement group_id="O3" value="99.4" lower_limit="98.0" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 19A (n=362,341,353)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="99.0" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.9" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="99.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 4</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.61</ci_lower_limit>
            <ci_upper_limit>1.81</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 4</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.39</ci_lower_limit>
            <ci_upper_limit>0.23</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 4</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.54</ci_lower_limit>
            <ci_upper_limit>0.20</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 6B</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.02</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 6B</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.03</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 6B</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.13</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 9V</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.25</ci_lower_limit>
            <ci_upper_limit>1.37</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 9V</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.76</ci_lower_limit>
            <ci_upper_limit>2.18</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 9V</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.87</ci_lower_limit>
            <ci_upper_limit>2.18</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 14</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.74</ci_lower_limit>
            <ci_upper_limit>1.62</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 14</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.03</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 14</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.61</ci_lower_limit>
            <ci_upper_limit>0.76</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 18C</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.52</ci_lower_limit>
            <ci_upper_limit>2.39</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 18C</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.30</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 18C</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.87</ci_lower_limit>
            <ci_upper_limit>0.74</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 19F</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.55</ci_lower_limit>
            <ci_upper_limit>1.50</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 19F</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.06</ci_lower_limit>
            <ci_upper_limit>0.57</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 19F</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.44</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 23F</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.21</ci_lower_limit>
            <ci_upper_limit>2.05</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 23F</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.52</ci_lower_limit>
            <ci_upper_limit>3.16</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 23F</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.05</ci_lower_limit>
            <ci_upper_limit>2.87</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 1</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.17</ci_lower_limit>
            <ci_upper_limit>2.53</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 1</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.20</ci_lower_limit>
            <ci_upper_limit>2.44</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 1</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.79</ci_lower_limit>
            <ci_upper_limit>1.66</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 3</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>2.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.85</ci_lower_limit>
            <ci_upper_limit>8.55</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 3</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-4.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.99</ci_lower_limit>
            <ci_upper_limit>0.21</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 3</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-7.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.14</ci_lower_limit>
            <ci_upper_limit>-2.37</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 5</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.00</ci_lower_limit>
            <ci_upper_limit>1.84</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 5</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.27</ci_lower_limit>
            <ci_upper_limit>1.30</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 5</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.84</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 6A</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.04</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 6A</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.76</ci_lower_limit>
            <ci_upper_limit>1.56</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 6A</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.83</ci_lower_limit>
            <ci_upper_limit>1.56</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 7F</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.47</ci_lower_limit>
            <ci_upper_limit>2.09</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 7F</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.48</ci_lower_limit>
            <ci_upper_limit>2.00</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 7F</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.59</ci_lower_limit>
            <ci_upper_limit>1.49</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 19A</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.04</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 19A</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.05</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 19A</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.09</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥1.00 Mcg/mL in the Combined 13vPnC Group 1 Month After the Infant Series</title>
        <description>Percentage of participants achieving predefined antibody threshold ≥1.00 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.</description>
        <time_frame>1 month after the infant series (7 months of age)</time_frame>
        <population>Evaluable immunogenicity population; (n)=number of subjects with a determinate IgG antibody concentration to the given serotype for the combined 13vPnC lot.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined 13vPnC</title>
            <description>Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1 or 2, or manufacturing lot at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥1.00 Mcg/mL in the Combined 13vPnC Group 1 Month After the Infant Series</title>
          <description>Percentage of participants achieving predefined antibody threshold ≥1.00 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.</description>
          <population>Evaluable immunogenicity population; (n)=number of subjects with a determinate IgG antibody concentration to the given serotype for the combined 13vPnC lot.</population>
          <units>observed percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common serotypes - serotype 4 (n=1213)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.7" lower_limit="68.1" upper_limit="73.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 6B (n=1206)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.9" lower_limit="76.4" upper_limit="81.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 9V (n=1210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.7" lower_limit="52.9" upper_limit="58.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 14 (n=1172)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.2" lower_limit="93.8" upper_limit="96.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 18C (n=1212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.7" lower_limit="66.0" upper_limit="71.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 19F (n=1205)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.4" lower_limit="83.3" upper_limit="87.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 23F (n=1212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.1" lower_limit="57.2" upper_limit="62.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 1 (n=1209)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.2" lower_limit="72.7" upper_limit="77.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 3 (n=1190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3" lower_limit="19.0" upper_limit="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 5 (n=1207)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.3" lower_limit="57.5" upper_limit="63.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 6A (n=1213)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.1" lower_limit="82.9" upper_limit="87.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 7F (n=1210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.8" lower_limit="91.2" upper_limit="94.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 19A (n=1211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.8" lower_limit="78.4" upper_limit="82.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥1.00 Mcg/mL in the Three 13vPnC Groups 1 Month After the Toddler Dose</title>
        <description>Percentage of participants achieving predefined antibody threshold ≥1.00 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.</description>
        <time_frame>1 month after the toddler dose (13 months of age)</time_frame>
        <population>Evaluable immunogenicity population; (n)=number of subjects with a determinate IgG antibody concentration to the given serotype for the three 13vPnC lots, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC (Pilot Lot 1)</title>
            <description>Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1 at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC (Pilot Lot 2)</title>
            <description>Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 2 at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>13vPnC (Manufacturing Lot)</title>
            <description>Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) manufacturing lot (manu lot) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥1.00 Mcg/mL in the Three 13vPnC Groups 1 Month After the Toddler Dose</title>
          <description>Percentage of participants achieving predefined antibody threshold ≥1.00 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.</description>
          <population>Evaluable immunogenicity population; (n)=number of subjects with a determinate IgG antibody concentration to the given serotype for the three 13vPnC lots, respectively.</population>
          <units>observed percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="415"/>
                <count group_id="O2" value="397"/>
                <count group_id="O3" value="408"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common serotypes - serotype 4 (n=364,342,355)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.0" lower_limit="82.0" upper_limit="89.4"/>
                    <measurement group_id="O2" value="87.4" lower_limit="83.4" upper_limit="90.7"/>
                    <measurement group_id="O3" value="92.7" lower_limit="89.5" upper_limit="95.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 6B (n=368,341,357)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.5" lower_limit="98.1" upper_limit="99.9"/>
                    <measurement group_id="O2" value="99.1" lower_limit="97.5" upper_limit="99.8"/>
                    <measurement group_id="O3" value="99.7" lower_limit="98.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 9V (n=368,342,357)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.7" lower_limit="76.3" upper_limit="84.6"/>
                    <measurement group_id="O2" value="84.5" lower_limit="80.2" upper_limit="88.2"/>
                    <measurement group_id="O3" value="85.4" lower_limit="81.3" upper_limit="88.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 14 (n=366,344,358)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.6" lower_limit="96.8" upper_limit="99.6"/>
                    <measurement group_id="O2" value="98.8" lower_limit="97.0" upper_limit="99.7"/>
                    <measurement group_id="O3" value="98.3" lower_limit="96.4" upper_limit="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 18C (n=362,341,354)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.6" lower_limit="75.0" upper_limit="83.6"/>
                    <measurement group_id="O2" value="85.0" lower_limit="80.8" upper_limit="88.7"/>
                    <measurement group_id="O3" value="89.5" lower_limit="85.9" upper_limit="92.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 19F (n=362,342,353)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.5" lower_limit="91.6" upper_limit="96.6"/>
                    <measurement group_id="O2" value="95.3" lower_limit="92.5" upper_limit="97.3"/>
                    <measurement group_id="O3" value="97.7" lower_limit="95.6" upper_limit="99.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 23F (n=362,340,353)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.7" lower_limit="88.4" upper_limit="94.3"/>
                    <measurement group_id="O2" value="91.2" lower_limit="87.6" upper_limit="94.0"/>
                    <measurement group_id="O3" value="89.8" lower_limit="86.2" upper_limit="92.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 1 (n=367,344,357)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.8" lower_limit="88.5" upper_limit="94.4"/>
                    <measurement group_id="O2" value="91.0" lower_limit="87.5" upper_limit="93.8"/>
                    <measurement group_id="O3" value="94.4" lower_limit="91.5" upper_limit="96.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 3 (n=366,343,356)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.0" lower_limit="27.2" upper_limit="37.0"/>
                    <measurement group_id="O2" value="30.3" lower_limit="25.5" upper_limit="35.5"/>
                    <measurement group_id="O3" value="36.8" lower_limit="31.8" upper_limit="42.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 5 (n=368,343,357)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.0" lower_limit="91.1" upper_limit="96.2"/>
                    <measurement group_id="O2" value="91.0" lower_limit="87.4" upper_limit="93.8"/>
                    <measurement group_id="O3" value="93.6" lower_limit="90.5" upper_limit="95.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 6A (n=366,342,355)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.2" lower_limit="97.6" upper_limit="99.8"/>
                    <measurement group_id="O2" value="98.2" lower_limit="96.2" upper_limit="99.4"/>
                    <measurement group_id="O3" value="99.2" lower_limit="97.6" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 7F (n=366,343,358)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.1" lower_limit="96.1" upper_limit="99.2"/>
                    <measurement group_id="O2" value="96.2" lower_limit="93.6" upper_limit="98.0"/>
                    <measurement group_id="O3" value="98.6" lower_limit="96.8" upper_limit="99.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 19A (n=362,341,353)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="99.0" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.4" lower_limit="97.9" upper_limit="99.9"/>
                    <measurement group_id="O3" value="99.7" lower_limit="98.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 4</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.52</ci_lower_limit>
            <ci_upper_limit>3.63</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 4</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-6.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.30</ci_lower_limit>
            <ci_upper_limit>-2.15</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 4</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-5.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.85</ci_lower_limit>
            <ci_upper_limit>-0.79</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 6B</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.19</ci_lower_limit>
            <ci_upper_limit>2.07</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 6B</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.69</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 6B</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.27</ci_lower_limit>
            <ci_upper_limit>0.75</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 9V</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-3.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.46</ci_lower_limit>
            <ci_upper_limit>1.82</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 9V</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-4.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.24</ci_lower_limit>
            <ci_upper_limit>0.76</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 9V</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.30</ci_lower_limit>
            <ci_upper_limit>4.41</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 14</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.14</ci_lower_limit>
            <ci_upper_limit>1.73</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 14</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.69</ci_lower_limit>
            <ci_upper_limit>2.39</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 14</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.46</ci_lower_limit>
            <ci_upper_limit>2.59</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 18C</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-5.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.17</ci_lower_limit>
            <ci_upper_limit>0.20</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 18C</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-10.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.31</ci_lower_limit>
            <ci_upper_limit>-4.70</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 18C</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-4.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.55</ci_lower_limit>
            <ci_upper_limit>0.46</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 19F</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.23</ci_lower_limit>
            <ci_upper_limit>2.52</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 19F</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-3.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.35</ci_lower_limit>
            <ci_upper_limit>-0.40</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 19F</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-2.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.44</ci_lower_limit>
            <ci_upper_limit>0.33</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 23F</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.67</ci_lower_limit>
            <ci_upper_limit>4.80</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 23F</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.38</ci_lower_limit>
            <ci_upper_limit>6.28</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 23F</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.06</ci_lower_limit>
            <ci_upper_limit>5.82</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 1</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.34</ci_lower_limit>
            <ci_upper_limit>5.08</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 1</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.39</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 1</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-3.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.45</ci_lower_limit>
            <ci_upper_limit>0.46</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 3</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.20</ci_lower_limit>
            <ci_upper_limit>8.55</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 3</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-4.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.79</ci_lower_limit>
            <ci_upper_limit>2.16</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 3</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-6.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.51</ci_lower_limit>
            <ci_upper_limit>0.54</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 5</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>3.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.84</ci_lower_limit>
            <ci_upper_limit>7.13</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 5</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.14</ci_lower_limit>
            <ci_upper_limit>4.11</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 5</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.72</ci_lower_limit>
            <ci_upper_limit>1.40</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 6A</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.87</ci_lower_limit>
            <ci_upper_limit>3.02</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 6A</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.62</ci_lower_limit>
            <ci_upper_limit>1.71</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 6A</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.00</ci_lower_limit>
            <ci_upper_limit>0.92</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 7F</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.62</ci_lower_limit>
            <ci_upper_limit>4.67</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 7F</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.67</ci_lower_limit>
            <ci_upper_limit>1.55</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 7F</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-2.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.11</ci_lower_limit>
            <ci_upper_limit>-0.01</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 19A</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.45</ci_lower_limit>
            <ci_upper_limit>2.10</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 19A</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.75</ci_lower_limit>
            <ci_upper_limit>1.58</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 19A</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence test of Wiens and Iglewicz used to evaluate consistency among the three 13vPnC lots.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.86</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
            <estimate_desc>Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in the Three 13vPnC Groups 1 Month After the Toddler Dose</title>
        <description>Antibody geometric mean concentration (GMC) as measured by mcg/mL for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.</description>
        <time_frame>1 month after the toddler dose (13 months of age)</time_frame>
        <population>Evaluable immunogenicity population; (n)=number of subjects with a determinate IgG antibody concentration to the given serotype for the three 13vPnC lots, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC (Pilot Lot 1)</title>
            <description>Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1 at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC (Pilot Lot 2)</title>
            <description>Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 2 at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>13vPnC (Manufacturing Lot)</title>
            <description>Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) manufacturing lot (manu lot) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in the Three 13vPnC Groups 1 Month After the Toddler Dose</title>
          <description>Antibody geometric mean concentration (GMC) as measured by mcg/mL for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.</description>
          <population>Evaluable immunogenicity population; (n)=number of subjects with a determinate IgG antibody concentration to the given serotype for the three 13vPnC lots, respectively.</population>
          <units>GMC mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="415"/>
                <count group_id="O2" value="397"/>
                <count group_id="O3" value="408"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common serotypes - serotype 4 (n=364,342,355)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.29" lower_limit="2.11" upper_limit="2.48"/>
                    <measurement group_id="O2" value="2.25" lower_limit="2.07" upper_limit="2.44"/>
                    <measurement group_id="O3" value="3.06" lower_limit="2.79" upper_limit="3.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 6B (n=368,341,357)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.14" lower_limit="10.24" upper_limit="12.11"/>
                    <measurement group_id="O2" value="9.33" lower_limit="8.55" upper_limit="10.19"/>
                    <measurement group_id="O3" value="9.92" lower_limit="9.15" upper_limit="10.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 9V (n=368,342,357)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.91" lower_limit="1.76" upper_limit="2.06"/>
                    <measurement group_id="O2" value="1.95" lower_limit="1.80" upper_limit="2.10"/>
                    <measurement group_id="O3" value="1.99" lower_limit="1.84" upper_limit="2.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 14 (n=366,344,358)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.61" lower_limit="6.06" upper_limit="7.22"/>
                    <measurement group_id="O2" value="7.05" lower_limit="6.42" upper_limit="7.74"/>
                    <measurement group_id="O3" value="6.91" lower_limit="6.32" upper_limit="7.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 18C (n=362,341,354)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.95" lower_limit="1.78" upper_limit="2.12"/>
                    <measurement group_id="O2" value="2.20" lower_limit="2.01" upper_limit="2.41"/>
                    <measurement group_id="O3" value="2.48" lower_limit="2.27" upper_limit="2.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 19F (n=362,342,353)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.51" lower_limit="4.05" upper_limit="5.03"/>
                    <measurement group_id="O2" value="4.67" lower_limit="4.23" upper_limit="5.14"/>
                    <measurement group_id="O3" value="6.51" lower_limit="5.91" upper_limit="7.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 23F (n=362,340,353)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.35" lower_limit="3.02" upper_limit="3.71"/>
                    <measurement group_id="O2" value="3.46" lower_limit="3.14" upper_limit="3.82"/>
                    <measurement group_id="O3" value="3.10" lower_limit="2.81" upper_limit="3.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 1 (n=367,344,357)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.75" lower_limit="2.53" upper_limit="2.99"/>
                    <measurement group_id="O2" value="2.95" lower_limit="2.68" upper_limit="3.24"/>
                    <measurement group_id="O3" value="3.01" lower_limit="2.75" upper_limit="3.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 3 (n=366,343,356)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" lower_limit="0.69" upper_limit="0.81"/>
                    <measurement group_id="O2" value="0.71" lower_limit="0.65" upper_limit="0.77"/>
                    <measurement group_id="O3" value="0.80" lower_limit="0.74" upper_limit="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 5 (n=368,343,357)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.11" lower_limit="2.87" upper_limit="3.37"/>
                    <measurement group_id="O2" value="2.63" lower_limit="2.42" upper_limit="2.87"/>
                    <measurement group_id="O3" value="2.80" lower_limit="2.60" upper_limit="3.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 6A (n=366,342,355)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.52" lower_limit="6.93" upper_limit="8.17"/>
                    <measurement group_id="O2" value="6.97" lower_limit="6.41" upper_limit="7.59"/>
                    <measurement group_id="O3" value="6.83" lower_limit="6.30" upper_limit="7.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotypes - serotype 7F (n=366,343,358)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.35" lower_limit="4.01" upper_limit="4.72"/>
                    <measurement group_id="O2" value="4.24" lower_limit="3.86" upper_limit="4.66"/>
                    <measurement group_id="O3" value="4.58" lower_limit="4.21" upper_limit="4.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 19A (n=362,341,353)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.41" lower_limit="7.73" upper_limit="9.14"/>
                    <measurement group_id="O2" value="8.32" lower_limit="7.66" upper_limit="9.04"/>
                    <measurement group_id="O3" value="8.60" lower_limit="7.91" upper_limit="9.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.10</ci_lower_limit>
            <ci_upper_limit>0.13</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.41</ci_lower_limit>
            <ci_upper_limit>-0.17</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.43</ci_lower_limit>
            <ci_upper_limit>-0.19</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 6B</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>0.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.06</ci_lower_limit>
            <ci_upper_limit>0.30</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 6B</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>0.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.00</ci_lower_limit>
            <ci_upper_limit>0.23</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 6B</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.18</ci_lower_limit>
            <ci_upper_limit>0.06</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 9V</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.13</ci_lower_limit>
            <ci_upper_limit>0.09</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 9V</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.15</ci_lower_limit>
            <ci_upper_limit>0.07</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 9V</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.13</ci_lower_limit>
            <ci_upper_limit>0.09</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 14</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.19</ci_lower_limit>
            <ci_upper_limit>0.06</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 14</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.17</ci_lower_limit>
            <ci_upper_limit>0.08</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 14</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.11</ci_lower_limit>
            <ci_upper_limit>0.15</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 18C</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.25</ci_lower_limit>
            <ci_upper_limit>0.00</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 18C</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.37</ci_lower_limit>
            <ci_upper_limit>-0.12</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 18C</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.25</ci_lower_limit>
            <ci_upper_limit>0.01</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 19F</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.18</ci_lower_limit>
            <ci_upper_limit>0.11</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 19F</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.51</ci_lower_limit>
            <ci_upper_limit>-0.22</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 19F</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.47</ci_lower_limit>
            <ci_upper_limit>-0.20</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 23F</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.17</ci_lower_limit>
            <ci_upper_limit>0.11</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 23F</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.07</ci_lower_limit>
            <ci_upper_limit>0.22</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Common serotypes - serotype 23F</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>0.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.03</ci_lower_limit>
            <ci_upper_limit>0.25</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.20</ci_lower_limit>
            <ci_upper_limit>0.06</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.21</ci_lower_limit>
            <ci_upper_limit>0.03</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.15</ci_lower_limit>
            <ci_upper_limit>0.11</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>0.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.06</ci_lower_limit>
            <ci_upper_limit>0.18</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.18</ci_lower_limit>
            <ci_upper_limit>0.04</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.25</ci_lower_limit>
            <ci_upper_limit>-0.01</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 5</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>0.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.05</ci_lower_limit>
            <ci_upper_limit>0.28</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 5</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>0.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.00</ci_lower_limit>
            <ci_upper_limit>0.21</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 5</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.17</ci_lower_limit>
            <ci_upper_limit>0.05</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 6A</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.04</ci_lower_limit>
            <ci_upper_limit>0.19</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 6A</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>0.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.02</ci_lower_limit>
            <ci_upper_limit>0.21</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 6A</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.10</ci_lower_limit>
            <ci_upper_limit>0.14</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 7F</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.10</ci_lower_limit>
            <ci_upper_limit>0.15</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 7F</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.17</ci_lower_limit>
            <ci_upper_limit>0.07</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 7F</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.20</ci_lower_limit>
            <ci_upper_limit>0.05</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 19A</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.11</ci_lower_limit>
            <ci_upper_limit>0.13</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 19A</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.14</ci_lower_limit>
            <ci_upper_limit>0.10</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Additional serotypes - serotype 19A</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in log-transformed GM</param_type>
            <param_value>-0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.15</ci_lower_limit>
            <ci_upper_limit>0.08</ci_upper_limit>
            <estimate_desc>2-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Local Reactions in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 1 (2 Months of Age)</title>
        <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Participants may be represented in more than 1 category.</description>
        <time_frame>Within 7 days after dose (2 months of age)</time_frame>
        <population>Safety population: all participants who received at least 1 dose of study vaccine. N=number of participants reporting any local reactions; (n)=number of participants reporting yes for at least 1 day or no for all days for the three 13vPnC groups and 7vPnC, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC (Pilot Lot 1)</title>
            <description>Participants received 1 single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1 at 2, 4, and 6 months of age (Infant series Dose 1, 2, and 3, respectively); coadministered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age (infant series).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC (Pilot Lot 2)</title>
            <description>Participants received 1 single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1 at 2, 4, and 6 months of age (Infant series Dose 1, 2, and 3, respectively); coadministered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age (infant series).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC (Manufacturing Lot)</title>
            <description>Participants received 1 single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1 at 2, 4, and 6 months of age (Infant series Dose 1, 2, and 3, respectively); coadministered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age (infant series).</description>
          </group>
          <group group_id="O4">
            <title>7vPnC</title>
            <description>Participants received 1 single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) pilot lot 1 at 2, 4, and 6 months of age (Infant series Dose 1, 2, and 3, respectively); coadministered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age (infant series).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Local Reactions in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 1 (2 Months of Age)</title>
          <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Participants may be represented in more than 1 category.</description>
          <population>Safety population: all participants who received at least 1 dose of study vaccine. N=number of participants reporting any local reactions; (n)=number of participants reporting yes for at least 1 day or no for all days for the three 13vPnC groups and 7vPnC, respectively.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="425"/>
                <count group_id="O2" value="416"/>
                <count group_id="O3" value="407"/>
                <count group_id="O4" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tenderness: Any (n=420, 409, 400, 212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.4"/>
                    <measurement group_id="O2" value="64.1"/>
                    <measurement group_id="O3" value="62.5"/>
                    <measurement group_id="O4" value="67.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness: Significant (n=348, 337, 345, 170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2"/>
                    <measurement group_id="O2" value="10.4"/>
                    <measurement group_id="O3" value="10.4"/>
                    <measurement group_id="O4" value="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration: Any (n=356, 347, 352, 176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.6"/>
                    <measurement group_id="O2" value="19.6"/>
                    <measurement group_id="O3" value="19.3"/>
                    <measurement group_id="O4" value="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration: Mild (n=353, 344, 348, 173)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7"/>
                    <measurement group_id="O2" value="16.9"/>
                    <measurement group_id="O3" value="15.5"/>
                    <measurement group_id="O4" value="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration: Moderate (n=338, 328, 340, 167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6"/>
                    <measurement group_id="O2" value="5.8"/>
                    <measurement group_id="O3" value="5.0"/>
                    <measurement group_id="O4" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration: Severe (n=333, 325, 335, 164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema: Any (n=355, 352, 360, 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4"/>
                    <measurement group_id="O2" value="25.0"/>
                    <measurement group_id="O3" value="23.1"/>
                    <measurement group_id="O4" value="22.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema: Mild (n=354, 352, 358, 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.1"/>
                    <measurement group_id="O2" value="24.7"/>
                    <measurement group_id="O3" value="21.2"/>
                    <measurement group_id="O4" value="21.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema: Moderate (n=334, 326, 337, 164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1"/>
                    <measurement group_id="O2" value="0.6"/>
                    <measurement group_id="O3" value="2.4"/>
                    <measurement group_id="O4" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema: Severe (n=333, 325, 335, 164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Local Reactions in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 2 (4 Months of Age)</title>
        <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 cm to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Participants may be represented in more than 1 category.</description>
        <time_frame>Within 7 days after dose (4 months of age)</time_frame>
        <population>Safety population: all participants who received at least 1 dose of study vaccine. N=number of participants reporting any local reactions; (n)=number of participants reporting yes for at least 1 day or no for all days for the three 13vPnC groups and 7vPnC, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC (Pilot Lot 1)</title>
            <description>Participants received 1 single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1 at 2, 4, and 6 months of age (Infant series Dose 1, 2, and 3, respectively); coadministered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age (infant series).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC (Pilot Lot 2)</title>
            <description>Participants received 1 single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1 at 2, 4, and 6 months of age (Infant series Dose 1, 2, and 3, respectively); coadministered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age (infant series).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC (Manufacturing Lot)</title>
            <description>Participants received 1 single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1 at 2, 4, and 6 months of age (Infant series Dose 1, 2, and 3, respectively); coadministered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age (infant series).</description>
          </group>
          <group group_id="O4">
            <title>7vPnC</title>
            <description>Participants received 1 single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) pilot lot 1 at 2, 4, and 6 months of age (Infant series Dose 1, 2, and 3, respectively); coadministered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age (infant series).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Local Reactions in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 2 (4 Months of Age)</title>
          <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 cm to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Participants may be represented in more than 1 category.</description>
          <population>Safety population: all participants who received at least 1 dose of study vaccine. N=number of participants reporting any local reactions; (n)=number of participants reporting yes for at least 1 day or no for all days for the three 13vPnC groups and 7vPnC, respectively.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="361"/>
                <count group_id="O2" value="345"/>
                <count group_id="O3" value="349"/>
                <count group_id="O4" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tenderness: Any (n=354, 330, 337, 176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.4"/>
                    <measurement group_id="O2" value="67.3"/>
                    <measurement group_id="O3" value="65.0"/>
                    <measurement group_id="O4" value="64.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness: Significant (n=269, 231, 262, 132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7"/>
                    <measurement group_id="O2" value="7.4"/>
                    <measurement group_id="O3" value="12.2"/>
                    <measurement group_id="O4" value="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration: Any (n=291, 248, 279, 141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.4"/>
                    <measurement group_id="O2" value="22.6"/>
                    <measurement group_id="O3" value="28.7"/>
                    <measurement group_id="O4" value="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration: Mild (n=288, 246, 276, 141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.6"/>
                    <measurement group_id="O2" value="22.0"/>
                    <measurement group_id="O3" value="26.8"/>
                    <measurement group_id="O4" value="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration: Moderate (n=270, 224, 255, 128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1"/>
                    <measurement group_id="O2" value="1.3"/>
                    <measurement group_id="O3" value="4.7"/>
                    <measurement group_id="O4" value="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration: Severe (n=263, 221, 250, 127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.4"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema: Any (n=292, 265, 281, 153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.1"/>
                    <measurement group_id="O2" value="35.8"/>
                    <measurement group_id="O3" value="34.5"/>
                    <measurement group_id="O4" value="30.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema: Mild (n=289, 263, 279, 153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.4"/>
                    <measurement group_id="O2" value="34.6"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="28.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema: Moderate (n=268, 223, 252, 128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4"/>
                    <measurement group_id="O2" value="1.8"/>
                    <measurement group_id="O3" value="3.2"/>
                    <measurement group_id="O4" value="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema: Severe (n=263, 221, 249, 127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Local Reactions in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 3 (6 Months of Age)</title>
        <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 cm to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Participants may be represented in more than 1 category.</description>
        <time_frame>Within 7 days after dose (6 months of age)</time_frame>
        <population>Safety population: all participants who received at least 1 dose of study vaccine. N=number of participants reporting any local reactions; (n)=number of participants reporting yes for at least 1 day or no for all days for the three 13vPnC groups and 7vPnC, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC (Pilot Lot 1)</title>
            <description>Participants received 1 single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1 at 2, 4, and 6 months of age (Infant series Dose 1, 2, and 3, respectively); coadministered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age (infant series).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC (Pilot Lot 2)</title>
            <description>Participants received 1 single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1 at 2, 4, and 6 months of age (Infant series Dose 1, 2, and 3, respectively); coadministered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age (infant series).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC (Manufacturing Lot)</title>
            <description>Participants received 1 single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1 at 2, 4, and 6 months of age (Infant series Dose 1, 2, and 3, respectively); coadministered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age (infant series).</description>
          </group>
          <group group_id="O4">
            <title>7vPnC</title>
            <description>Participants received 1 single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) pilot lot 1 at 2, 4, and 6 months of age (Infant series Dose 1, 2, and 3, respectively); coadministered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age (infant series).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Local Reactions in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 3 (6 Months of Age)</title>
          <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 cm to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Participants may be represented in more than 1 category.</description>
          <population>Safety population: all participants who received at least 1 dose of study vaccine. N=number of participants reporting any local reactions; (n)=number of participants reporting yes for at least 1 day or no for all days for the three 13vPnC groups and 7vPnC, respectively.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="333"/>
                <count group_id="O2" value="321"/>
                <count group_id="O3" value="320"/>
                <count group_id="O4" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tenderness: Any (n=317, 304, 300, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5"/>
                    <measurement group_id="O2" value="60.9"/>
                    <measurement group_id="O3" value="55.0"/>
                    <measurement group_id="O4" value="64.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness: Significant (n=248, 226, 237, 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9"/>
                    <measurement group_id="O2" value="7.5"/>
                    <measurement group_id="O3" value="10.1"/>
                    <measurement group_id="O4" value="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration: Any (n=263, 250, 262, 128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.0"/>
                    <measurement group_id="O2" value="23.6"/>
                    <measurement group_id="O3" value="28.6"/>
                    <measurement group_id="O4" value="30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration: Mild (n=260, 249, 260, 127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.6"/>
                    <measurement group_id="O2" value="22.5"/>
                    <measurement group_id="O3" value="27.3"/>
                    <measurement group_id="O4" value="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration: Moderate (n=242, 221, 229, 114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1"/>
                    <measurement group_id="O2" value="4.1"/>
                    <measurement group_id="O3" value="3.9"/>
                    <measurement group_id="O4" value="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration: Severe (n=237, 217, 227, 111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema: Any (n=278, 262, 274, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.6"/>
                    <measurement group_id="O2" value="35.9"/>
                    <measurement group_id="O3" value="37.6"/>
                    <measurement group_id="O4" value="39.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema: Mild (n=275, 260, 272, 135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.1"/>
                    <measurement group_id="O2" value="33.8"/>
                    <measurement group_id="O3" value="36.4"/>
                    <measurement group_id="O4" value="38.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema: Moderate (n=243, 219, 231, 116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3"/>
                    <measurement group_id="O2" value="4.1"/>
                    <measurement group_id="O3" value="5.6"/>
                    <measurement group_id="O4" value="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema: Severe (n=237, 217, 227, 111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Local Reactions in the Combined 13vPnC Group and 7vPnC Group: Toddler Dose (12 Months of Age)</title>
        <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 cm to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Participants may be represented in more than 1 category.</description>
        <time_frame>Within 7 days after dose (12 months of age)</time_frame>
        <population>Safety population: all participants who received at least 1 dose of study vaccine. N=number of participants reporting any local reactions; (n)=number of participants reporting yes for at least 1 day or no for all days for the combined 13vPnC group and 7vPnC, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined 13vPnC</title>
            <description>Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1 or 2, or manufacturing lot at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>Participants received 1 single 0.5 milliliter (mL) dose of 7-valent pneumococcal conjugate vaccine (7vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Local Reactions in the Combined 13vPnC Group and 7vPnC Group: Toddler Dose (12 Months of Age)</title>
          <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 cm to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Participants may be represented in more than 1 category.</description>
          <population>Safety population: all participants who received at least 1 dose of study vaccine. N=number of participants reporting any local reactions; (n)=number of participants reporting yes for at least 1 day or no for all days for the combined 13vPnC group and 7vPnC, respectively.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="889"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tenderness: Any (n=826, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.3"/>
                    <measurement group_id="O2" value="63.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness: Significant (n=630, 97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7"/>
                    <measurement group_id="O2" value="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration: Any (n=698, 110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.5"/>
                    <measurement group_id="O2" value="43.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration: Mild (n=689, 107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.9"/>
                    <measurement group_id="O2" value="41.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration: Moderate (n=627, 101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5"/>
                    <measurement group_id="O2" value="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration: Severe (n=603, 93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema: Any (n=749, 121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.6"/>
                    <measurement group_id="O2" value="52.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema: Mild (n=735, 116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.2"/>
                    <measurement group_id="O2" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema: Moderate (n=631, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6"/>
                    <measurement group_id="O2" value="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema: Severe (n=603, 93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Systemic Events in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 1 (2 Months of Age)</title>
        <description>Systemic events (any fever ≥ 38 degrees Celsius [C], decreased appetite, irritability, increased sleep, decreased sleep, and hives [urticaria]) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
        <time_frame>Within 7 days after dose (2 months of age)</time_frame>
        <population>Safety population: all participants who received at least 1 dose of study vaccine. N=number of participants reporting any systemic events; (n)=number of participants reporting yes for at least 1 day or no for all days for the three 13vPnC groups and 7vPnC, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC (Pilot Lot 1)</title>
            <description>Participants received 1 single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1 at 2, 4, and 6 months of age (Infant series Dose 1, 2, and 3, respectively); coadministered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age (infant series).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC (Pilot Lot 2)</title>
            <description>Participants received 1 single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1 at 2, 4, and 6 months of age (Infant series Dose 1, 2, and 3, respectively); coadministered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age (infant series).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC (Manufacturing Lot)</title>
            <description>Participants received 1 single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1 at 2, 4, and 6 months of age (Infant series Dose 1, 2, and 3, respectively); coadministered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age (infant series).</description>
          </group>
          <group group_id="O4">
            <title>7vPnC</title>
            <description>Participants received 1 single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) pilot lot 1 at 2, 4, and 6 months of age (Infant series Dose 1, 2, and 3, respectively); coadministered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age (infant series).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Systemic Events in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 1 (2 Months of Age)</title>
          <description>Systemic events (any fever ≥ 38 degrees Celsius [C], decreased appetite, irritability, increased sleep, decreased sleep, and hives [urticaria]) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
          <population>Safety population: all participants who received at least 1 dose of study vaccine. N=number of participants reporting any systemic events; (n)=number of participants reporting yes for at least 1 day or no for all days for the three 13vPnC groups and 7vPnC, respectively.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="465"/>
                <count group_id="O2" value="457"/>
                <count group_id="O3" value="456"/>
                <count group_id="O4" value="237"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever ≥38 but ≤39 degrees C (n=353, 337, 353, 173)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.6"/>
                    <measurement group_id="O2" value="23.4"/>
                    <measurement group_id="O3" value="24.6"/>
                    <measurement group_id="O4" value="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;39 but ≤40 degrees C (n=328, 319, 333, 161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                    <measurement group_id="O2" value="0.3"/>
                    <measurement group_id="O3" value="0.9"/>
                    <measurement group_id="O4" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;40 degrees C (n=328, 319, 331, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.3"/>
                    <measurement group_id="O4" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite (n=393, 385, 386, 200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.6"/>
                    <measurement group_id="O2" value="46.0"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="49.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (n=435, 432, 433, 226)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.7"/>
                    <measurement group_id="O2" value="84.3"/>
                    <measurement group_id="O3" value="89.1"/>
                    <measurement group_id="O4" value="87.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased sleep (n=425, 417, 402, 212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.5"/>
                    <measurement group_id="O2" value="72.7"/>
                    <measurement group_id="O3" value="69.4"/>
                    <measurement group_id="O4" value="72.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased sleep (n=379, 377, 377, 194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.1"/>
                    <measurement group_id="O2" value="46.9"/>
                    <measurement group_id="O3" value="42.2"/>
                    <measurement group_id="O4" value="46.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hives [urticaria] (n=333, 328, 335, 164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                    <measurement group_id="O2" value="0.9"/>
                    <measurement group_id="O3" value="0.6"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Systemic Events in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 2 (4 Months of Age)</title>
        <description>Systemic events (any fever ≥ 38 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives [urticaria]) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
        <time_frame>Within 7 days after dose (4 months of age)</time_frame>
        <population>Safety population: all participants who received at least 1 dose of study vaccine. N=number of participants reporting any systemic events; (n)=number of participants reporting yes for at least 1 day or no for all days for the three 13vPnC groups and 7vPnC, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC (Pilot Lot 1)</title>
            <description>Participants received 1 single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1 at 2, 4, and 6 months of age (Infant series Dose 1, 2, and 3, respectively); coadministered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age (infant series).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC (Pilot Lot 2)</title>
            <description>Participants received 1 single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1 at 2, 4, and 6 months of age (Infant series Dose 1, 2, and 3, respectively); coadministered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age (infant series).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC (Manufacturing Lot)</title>
            <description>Participants received 1 single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1 at 2, 4, and 6 months of age (Infant series Dose 1, 2, and 3, respectively); coadministered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age (infant series).</description>
          </group>
          <group group_id="O4">
            <title>7vPnC</title>
            <description>Participants received 1 single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) pilot lot 1 at 2, 4, and 6 months of age (Infant series Dose 1, 2, and 3, respectively); coadministered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age (infant series).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Systemic Events in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 2 (4 Months of Age)</title>
          <description>Systemic events (any fever ≥ 38 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives [urticaria]) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
          <population>Safety population: all participants who received at least 1 dose of study vaccine. N=number of participants reporting any systemic events; (n)=number of participants reporting yes for at least 1 day or no for all days for the three 13vPnC groups and 7vPnC, respectively.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="400"/>
                <count group_id="O2" value="398"/>
                <count group_id="O3" value="410"/>
                <count group_id="O4" value="208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever ≥38 but ≤39 degrees C (n=290, 250, 290, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.4"/>
                    <measurement group_id="O2" value="36.4"/>
                    <measurement group_id="O3" value="35.5"/>
                    <measurement group_id="O4" value="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;39 but ≤40 degrees C (n=263, 216, 248, 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4"/>
                    <measurement group_id="O2" value="3.2"/>
                    <measurement group_id="O3" value="3.6"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;40 degrees C (n=259, 214, 245, 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite (n=322, 293, 325, 164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.4"/>
                    <measurement group_id="O2" value="49.1"/>
                    <measurement group_id="O3" value="48.0"/>
                    <measurement group_id="O4" value="49.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (n=377, 370, 376, 201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.5"/>
                    <measurement group_id="O2" value="86.5"/>
                    <measurement group_id="O3" value="84.6"/>
                    <measurement group_id="O4" value="81.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased sleep (n=332, 318, 343, 177)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.8"/>
                    <measurement group_id="O2" value="68.2"/>
                    <measurement group_id="O3" value="67.3"/>
                    <measurement group_id="O4" value="63.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased sleep (n=324, 291, 305, 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.1"/>
                    <measurement group_id="O2" value="48.8"/>
                    <measurement group_id="O3" value="44.6"/>
                    <measurement group_id="O4" value="48.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hives [urticaria] (n=263, 225, 253, 127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="2.2"/>
                    <measurement group_id="O3" value="1.6"/>
                    <measurement group_id="O4" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Systemic Events in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 3 (6 Months of Age)</title>
        <description>Systemic events (any fever ≥ 38 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives [urticaria]) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
        <time_frame>Within 7 days after dose (6 months of age)</time_frame>
        <population>Safety population: all participants who received at least 1 dose of study vaccine. N=number of participants reporting any systemic events; (n)=number of participants reporting yes for at least 1 day or no for all days for the three 13vPnC groups and 7vPnC, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC (Pilot Lot 1)</title>
            <description>Participants received 1 single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1 at 2, 4, and 6 months of age (Infant series Dose 1, 2, and 3, respectively); coadministered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age (infant series).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC (Pilot Lot 2)</title>
            <description>Participants received 1 single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1 at 2, 4, and 6 months of age (Infant series Dose 1, 2, and 3, respectively); coadministered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age (infant series).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC (Manufacturing Lot)</title>
            <description>Participants received 1 single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1 at 2, 4, and 6 months of age (Infant series Dose 1, 2, and 3, respectively); coadministered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age (infant series).</description>
          </group>
          <group group_id="O4">
            <title>7vPnC</title>
            <description>Participants received 1 single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) pilot lot 1 at 2, 4, and 6 months of age (Infant series Dose 1, 2, and 3, respectively); coadministered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age (infant series).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Systemic Events in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 3 (6 Months of Age)</title>
          <description>Systemic events (any fever ≥ 38 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives [urticaria]) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
          <population>Safety population: all participants who received at least 1 dose of study vaccine. N=number of participants reporting any systemic events; (n)=number of participants reporting yes for at least 1 day or no for all days for the three 13vPnC groups and 7vPnC, respectively.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="373"/>
                <count group_id="O2" value="365"/>
                <count group_id="O3" value="373"/>
                <count group_id="O4" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever ≥38 but ≤39 degrees C (n=266, 246, 252, 132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.3"/>
                    <measurement group_id="O2" value="27.6"/>
                    <measurement group_id="O3" value="31.7"/>
                    <measurement group_id="O4" value="32.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;39 but ≤40 degrees C (n=237, 219, 231, 113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5"/>
                    <measurement group_id="O2" value="3.7"/>
                    <measurement group_id="O3" value="5.6"/>
                    <measurement group_id="O4" value="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;40 degrees C (n=234, 216, 224, 111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.5"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite (n=286, 273, 286, 144)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.8"/>
                    <measurement group_id="O2" value="48.0"/>
                    <measurement group_id="O3" value="50.7"/>
                    <measurement group_id="O4" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (n=352, 339, 347, 186)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.5"/>
                    <measurement group_id="O2" value="80.5"/>
                    <measurement group_id="O3" value="82.7"/>
                    <measurement group_id="O4" value="84.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased sleep (n=289, 289, 286, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.4"/>
                    <measurement group_id="O2" value="58.8"/>
                    <measurement group_id="O3" value="59.8"/>
                    <measurement group_id="O4" value="51.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased sleep (n=282, 272, 289, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.6"/>
                    <measurement group_id="O2" value="50.4"/>
                    <measurement group_id="O3" value="48.4"/>
                    <measurement group_id="O4" value="56.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hives [urticaria] (n=239, 218, 229, 112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="0.9"/>
                    <measurement group_id="O3" value="1.7"/>
                    <measurement group_id="O4" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Systemic Events in the Combined 13vPnC Group and 7vPnC Group: Toddler Dose (12 Months of Age)</title>
        <description>Systemic events (any fever ≥ 38 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives [urticaria]) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
        <time_frame>Within 7 days after dose (12 months of age)</time_frame>
        <population>Safety population: all participants who received at least 1 dose of study vaccine. N=number of participants reporting any systemic events; (n)=number of participants reporting yes for at least 1 day or no for all days for the combined 13vPnC group and 7vPnC, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined 13vPnC</title>
            <description>Participants received 1 single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1 or 2, or manufacturing lot at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>Participants received 1 single 0.5 milliliter (mL) dose of 7-valent pneumococcal conjugate vaccine (7vPnC) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age; a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Systemic Events in the Combined 13vPnC Group and 7vPnC Group: Toddler Dose (12 Months of Age)</title>
          <description>Systemic events (any fever ≥ 38 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives [urticaria]) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
          <population>Safety population: all participants who received at least 1 dose of study vaccine. N=number of participants reporting any systemic events; (n)=number of participants reporting yes for at least 1 day or no for all days for the combined 13vPnC group and 7vPnC, respectively.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1001"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever ≥38 but ≤39 degrees C (n=667, 107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.8"/>
                    <measurement group_id="O2" value="29.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;39 but ≤40 degrees C (n=592, 95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4"/>
                    <measurement group_id="O2" value="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;40 degrees C (n=586, 93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite (n=790, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.9"/>
                    <measurement group_id="O2" value="50.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (n=943, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.8"/>
                    <measurement group_id="O2" value="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased sleep (n=779, 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.8"/>
                    <measurement group_id="O2" value="47.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased sleep (n=770, 117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.9"/>
                    <measurement group_id="O2" value="42.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hives [urticaria] (n=607, 96)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1"/>
                    <measurement group_id="O2" value="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline through 6 Month Follow-up after last study vaccination (18 Months). Local reactions and systemic events assessed within 7 days of dose: Infant Series Dose 1, 2, and 3 at 2, 4, and 6 months of age, respectively; Toddler Dose at 12 months of age.</time_frame>
      <desc>Safety population = all randomized subjects with at least 1 dose of study treatment. An Adverse Event (AE) term may be reported as both a serious and non-serious AE, but are distinct events. AE may = serious for 1 subject and = non-serious for another subject or subject may have experienced both a serious and non-serious episode of the same event.</desc>
      <group_list>
        <group group_id="E1">
          <title>Infant Series 13vPnC (Pilot Lot 1)</title>
          <description>Participants received 1 single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1 at 2, 4, and 6 months of age (infant series); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age (infant series).
Other Adverse Events (non-serious events): the number affected (N) for non-systematic (unsolicited) Other Adverse Events N=407; systematic (solicited) Local Reactions N=262; systematic (solicited) Systemic Events N=373.</description>
        </group>
        <group group_id="E2">
          <title>Infant Series 13vPnC (Pilot Lot 2)</title>
          <description>Participants received 1 single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 2 at 2, 4, and 6 months of age (infant series); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age (infant series).
Other Adverse Events (non-serious events): the number affected (N) for non-systematic (unsolicited) Other Adverse Events N=394; systematic (solicited) Local Reactions N=262; systematic (solicited) Systemic Events N=364.</description>
        </group>
        <group group_id="E3">
          <title>Infant Series 13vPnC (Manufacturing Lot)</title>
          <description>Participants received 1 single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) manufacturing lot (manu lot) at 2, 4, and 6 months of age (infant series); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age (infant series).
Other Adverse Events (non-serious events): the number affected (N) for non-systematic (unsolicited) Other Adverse Events N=402; systematic (solicited) Local Reactions N=250; systematic (solicited) Systemic Events N=386.</description>
        </group>
        <group group_id="E4">
          <title>Infant Series 7vPnC</title>
          <description>Participants received 1 single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) at 2, 4, and 6 months of age (infant series); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age (infant series).
Other Adverse Events (non-serious events): the number affected (N) for non-systematic (unsolicited) Other Adverse Events N=207; systematic (solicited) Local Reactions N=142; systematic (solicited) Systemic Events N=198.</description>
        </group>
        <group group_id="E5">
          <title>After the Infant Series Combined 13vPnC</title>
          <description>Participants received 1 single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1, 2, or manufacturing lot at 2, 4, and 6 months of age (assessment at 7 months of age; 1 month after the infant series); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age(assessment at 7 months of age; 1 month after the infant series).</description>
        </group>
        <group group_id="E6">
          <title>After the Infant Series 7vPnC</title>
          <description>Participants received 1 single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) at 2, 4, and 6 months of age (assessment at 7 months of age; 1 month after the infant series); co-administered with Pediarix® (a commercially available combination diphtheria and tetanus toxoid; acellular pertussis and hepatitis B antigens; and inactivated poliovirus); and a commercially available Haemophilus influenzae type b (Hib) vaccine at 2, 4, and 6 months of age(assessment at 7 months of age; 1 month after the infant series).</description>
        </group>
        <group group_id="E7">
          <title>Toddler Dose Combined 13vPnC</title>
          <description>Participants received 1 single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1, 2, or manufacturing lot at 12 months of age; co-administered with a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.
Other Adverse Events (non-serious events): the number affected (N) for non-systematic (unsolicited) Other Adverse Events N=434; systematic (solicited) Local Reactions N=473; systematic (solicited) Systemic Events N=771.</description>
        </group>
        <group group_id="E8">
          <title>Toddler Dose 7vPnC</title>
          <description>Participants received 1 single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) at 12 months of age; co-administered with a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age.
Other Adverse Events (non-serious events): the number affected (N) for non-systematic (unsolicited) Other Adverse Events N=75; systematic (solicited) Local Reactions N=83; systematic (solicited) Systemic Events N=128.</description>
        </group>
        <group group_id="E9">
          <title>Post Toddler Dose 6-Month Follow-up Combined 13vPnC</title>
          <description>Participants received 1 single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC) pilot lot 1, 2, or manufacturing lot at 12 months of age (assessment at 18 months of age; 6 months after the toddler dose) ; co-administered with a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age (assessment at 18 months of age; 6 months after the toddler dose).</description>
        </group>
        <group group_id="E10">
          <title>Post Toddler Dose 6-Month Follow-up 7vPnC</title>
          <description>Participants received 1 single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) at 12 months of age (assessment at 18 months of age; 6 months after the toddler dose) ; co-administered with a commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella), or if not available, a commercially available MMR and a commercially available varicella vaccine administered in separate injections; and a commercially available hepatitis A vaccine (HAV) administered at 12 months of age (assessment at 18 months of age; 6 months after the toddler dose).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="21" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cyanosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pulmonary valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dacryostenosis acquired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Sudden infant death syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Injection site rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to vaccine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Abscess oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Meningitis aseptic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Meningitis enteroviral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Eczema herpeticum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Herpangina</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Streptococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Cellulitis pharyngeal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Viral rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Endocarditis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Near drowning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Foreign body trauma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Abnormal loss of weight</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Apparent life threatening event</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Stridor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="407" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="394" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="402" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="207" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="88" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="771" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="128" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="37" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="9" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Thrombocythaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cyanosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Plagiocephaly</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Dacryostenosis congenital</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Macrocephaly</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pectus excavatum</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Ankyloglossia congenital</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Brachycephaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hemihypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hip dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hypospadias</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Laryngomalacia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Naevus flammeus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Phimosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pulmonary valve stenosis congenital</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Skull malformation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Ventricular septal defect</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Von Willebrand's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Congenital neavus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Tibial torsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Middle ear effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Cerumen impaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Otorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Deafness neurosensory</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>External ear inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Tympanic membrane disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Tympanic membrane perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Precocious puberty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="17" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Dacryostenosis acquired</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Eye discharge</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Strabismus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Eye swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Eyelid ptosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Dark circles under eyes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Heterophoria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hypermetropia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pupillary reflex impaired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pupils unequal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Scleral disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="37" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="17" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Teething</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Infantile spitting up</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Stomach discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Abnormal faeces</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Frequent bowel movements</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Infantile colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Allergic colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Dyschezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Gingval cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Gingval ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Mouth cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Oral disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Regurgitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Retching</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Tongue discolouration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Tongue geographic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Vomiting projectile</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Anal skin tags</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="38" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Xerosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Injection site dryness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Injection site rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Injection site urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Developmental delay</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Localised oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever ≥ 38 degrees Celsius C but ≤ 39 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Fever ≥ 38 degrees Celsius C but ≤ 39 degrees C.</description>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="337"/>
                <counts group_id="E3" subjects_affected="87" subjects_at_risk="353"/>
                <counts group_id="E4" subjects_affected="45" subjects_at_risk="173"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="192" subjects_at_risk="667"/>
                <counts group_id="E8" subjects_affected="32" subjects_at_risk="107"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever ≥ 38 degrees Celsius C but ≤ 39 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Fever ≥ 38 degrees Celsius C but ≤ 39 degrees C.</description>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="103" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="143"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever ≥ 38 degrees Celsius C but ≤ 39 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Fever ≥ 38 degrees Celsius C but ≤ 39 degrees C</description>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="246"/>
                <counts group_id="E3" subjects_affected="80" subjects_at_risk="252"/>
                <counts group_id="E4" subjects_affected="43" subjects_at_risk="132"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt; 39 degrees C but ≤ 40 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Fever &gt; 39 degrees C but ≤ 40 degrees C.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="333"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="26" subjects_at_risk="592"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="95"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt; 39 degrees C but ≤ 40 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Fever &gt; 39 degrees C but ≤ 40 degrees C.</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="216"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="248"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt; 39 degrees C but ≤ 40 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Fever &gt; 39 degrees C but ≤ 40 degrees C.</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="219"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="231"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="113"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt; 40 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Fever &gt; 40 degrees C.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="586"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt; 40 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Fever &gt; 40 degrees C.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt; 40 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Fever &gt; 40 degrees C.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Decreased appetite.</description>
                <counts group_id="E1" subjects_affected="199" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="177" subjects_at_risk="385"/>
                <counts group_id="E3" subjects_affected="193" subjects_at_risk="386"/>
                <counts group_id="E4" subjects_affected="98" subjects_at_risk="200"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="410" subjects_at_risk="790"/>
                <counts group_id="E8" subjects_affected="58" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Decreased appetite.</description>
                <counts group_id="E1" subjects_affected="156" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="144" subjects_at_risk="293"/>
                <counts group_id="E3" subjects_affected="156" subjects_at_risk="325"/>
                <counts group_id="E4" subjects_affected="81" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Decreased appetite.</description>
                <counts group_id="E1" subjects_affected="131" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="131" subjects_at_risk="273"/>
                <counts group_id="E3" subjects_affected="145" subjects_at_risk="286"/>
                <counts group_id="E4" subjects_affected="72" subjects_at_risk="144"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Irritability.</description>
                <counts group_id="E1" subjects_affected="373" subjects_at_risk="435"/>
                <counts group_id="E2" subjects_affected="364" subjects_at_risk="432"/>
                <counts group_id="E3" subjects_affected="386" subjects_at_risk="433"/>
                <counts group_id="E4" subjects_affected="198" subjects_at_risk="226"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="771" subjects_at_risk="943"/>
                <counts group_id="E8" subjects_affected="128" subjects_at_risk="160"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Irritability.</description>
                <counts group_id="E1" subjects_affected="326" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="320" subjects_at_risk="370"/>
                <counts group_id="E3" subjects_affected="318" subjects_at_risk="376"/>
                <counts group_id="E4" subjects_affected="163" subjects_at_risk="201"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Irritability.</description>
                <counts group_id="E1" subjects_affected="280" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="273" subjects_at_risk="339"/>
                <counts group_id="E3" subjects_affected="287" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="157" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Increased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Increased sleep.</description>
                <counts group_id="E1" subjects_affected="304" subjects_at_risk="425"/>
                <counts group_id="E2" subjects_affected="303" subjects_at_risk="417"/>
                <counts group_id="E3" subjects_affected="279" subjects_at_risk="402"/>
                <counts group_id="E4" subjects_affected="154" subjects_at_risk="212"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="372" subjects_at_risk="779"/>
                <counts group_id="E8" subjects_affected="60" subjects_at_risk="126"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Increased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Increased sleep.</description>
                <counts group_id="E1" subjects_affected="215" subjects_at_risk="332"/>
                <counts group_id="E2" subjects_affected="217" subjects_at_risk="318"/>
                <counts group_id="E3" subjects_affected="231" subjects_at_risk="343"/>
                <counts group_id="E4" subjects_affected="112" subjects_at_risk="177"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Increased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Increased sleep.</description>
                <counts group_id="E1" subjects_affected="160" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="170" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="171" subjects_at_risk="286"/>
                <counts group_id="E4" subjects_affected="71" subjects_at_risk="138"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Decreased sleep.</description>
                <counts group_id="E1" subjects_affected="167" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="177" subjects_at_risk="377"/>
                <counts group_id="E3" subjects_affected="159" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="90" subjects_at_risk="194"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="361" subjects_at_risk="770"/>
                <counts group_id="E8" subjects_affected="50" subjects_at_risk="117"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Decreased sleep.</description>
                <counts group_id="E1" subjects_affected="159" subjects_at_risk="324"/>
                <counts group_id="E2" subjects_affected="142" subjects_at_risk="291"/>
                <counts group_id="E3" subjects_affected="136" subjects_at_risk="305"/>
                <counts group_id="E4" subjects_affected="77" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Decreased sleep.</description>
                <counts group_id="E1" subjects_affected="120" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="137" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="140" subjects_at_risk="289"/>
                <counts group_id="E4" subjects_affected="83" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Hives (Urticaria)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Hives (Urticaria).</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="335"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="13" subjects_at_risk="607"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Hives (Urticaria)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Hives (Urticaria).</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Hives (Urticaria)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Hives (Urticaria).</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Milk allergy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Allergy to vaccine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="194" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="187" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="204" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="97" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="62" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="142" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="125" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="135" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="85" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="70" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="20" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="66" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="44" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="20" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Candida nappy rash</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Viral skin infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Skin candida</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Conjunctivitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Herpangina</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Roseola</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Dacryocystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Conjunctivitis infective</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Viral pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Intertrigo candida</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Beta haemolytic streptococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Body tinea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Dermatophytosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Gastritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Tinea capitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Tinea infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Abscess oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Breast cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Cellulitis of male external genital organ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Cellulitis staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Eczema herpeticum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Eczema infected</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Erythema infectiosum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Genital candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Rotavirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Scarlet fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Staphylococcal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Viraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Viral diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Otitis media chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Coxsackie viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Viral rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Dermatitis infected</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hand-foot-and-mouth disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Adenovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Exanthema subitum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Lyme disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Traumatic brain injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Chemical burns of eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Corneal abrasion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1433"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Mouth injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Torus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Vaccination complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Cardiac murmur functional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Head circumference abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Blood lead increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Body height below normal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Weight gain poor</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Food intolerance</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Feeding disorder neonatal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Cow's milk intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Lactose intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Oral intake reduced</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Overweight</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Underweight</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Torticollis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Head deformity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Muscle twiching</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Knee deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Haemangioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Haemangioma of skin</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Benign neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Benign penile neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Fibrous histiocytoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hypertonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Head titubation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hyporeflexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hypotonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Poor quality sleep</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Psychomotor hyperactivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Subdural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Cerebral cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Speech disorder developmental</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Gross motor delay</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Cephalhaematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Neonatal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Umbilical granuloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Breath holding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Initial insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Screaming</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Tic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urine odour abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Vesicoureteric reflux</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Renal tubular acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vulval disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Penile adhesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Balanitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Breast cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Genital discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Gynaecomastia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Genital labial adhesions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Genital rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Penile oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="22" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="22" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="10" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Stridor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Tracheomalacia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Choking</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Postnasal drip</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Rhinitis seasonal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Rhonchi</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="17" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="31" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="27" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Seborrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Heat rash</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Dandruff</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Acne infantile</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Intertrigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Acanthosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Ingrowing nail</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Post inflammatory pigmentation change</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Cafe au lait spots</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Dermographism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Eczema infantile</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Livedo reticularis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Nail discolouration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pityriasis alba</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Rash neonatal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Rash vesicular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Skin fissures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Skin nodule</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Subcutaneous nodule</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Urticaria papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Keratosis pilaris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Vitiligo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Acrodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pityriasis rosea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Tenderness (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Tenderness (any)=present at site of vaccination.</description>
                <counts group_id="E1" subjects_affected="262" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="262" subjects_at_risk="409"/>
                <counts group_id="E3" subjects_affected="250" subjects_at_risk="400"/>
                <counts group_id="E4" subjects_affected="142" subjects_at_risk="212"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="473" subjects_at_risk="826"/>
                <counts group_id="E8" subjects_affected="83" subjects_at_risk="131"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Tenderness (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Tenderness (any)=present at site of vaccination.</description>
                <counts group_id="E1" subjects_affected="235" subjects_at_risk="354"/>
                <counts group_id="E2" subjects_affected="222" subjects_at_risk="330"/>
                <counts group_id="E3" subjects_affected="219" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="114" subjects_at_risk="176"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Tenderness (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Tenderness (any)=present at site of vaccination.</description>
                <counts group_id="E1" subjects_affected="198" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="185" subjects_at_risk="304"/>
                <counts group_id="E3" subjects_affected="165" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="101" subjects_at_risk="156"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Tenderness (significant)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Tenderness (significant)=present and interfered with limb movement.</description>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="337"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="345"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="170"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="42" subjects_at_risk="630"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Tenderness (significant)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Tenderness (significant)=present and interfered with limb movement.</description>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="262"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="132"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Tenderness (significant)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Tenderness (significant)=present and interfered with limb movement.</description>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="248"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="237"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="118"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Induration (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Induration (any)=present at site of vaccination.</description>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="347"/>
                <counts group_id="E3" subjects_affected="68" subjects_at_risk="352"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="176"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="220" subjects_at_risk="698"/>
                <counts group_id="E8" subjects_affected="48" subjects_at_risk="110"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Induration (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Induration (any)=present at site of vaccination.</description>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="248"/>
                <counts group_id="E3" subjects_affected="80" subjects_at_risk="279"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Induration (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Induration (any)=present at site of vaccination.</description>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="75" subjects_at_risk="262"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Induration (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Induration (mild)=0.5 centimeters (cm) to 2.0 cm.</description>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="344"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="348"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="173"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="199" subjects_at_risk="689"/>
                <counts group_id="E8" subjects_affected="44" subjects_at_risk="107"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Induration (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Induration (mild)=0.5 cm to 2.0 cm.</description>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="246"/>
                <counts group_id="E3" subjects_affected="74" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Induration (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Induration (mild)=0.5 cm to 2.0 cm.</description>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="260"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="71" subjects_at_risk="260"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="127"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Induration (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Induration (moderate)=2.5 cm to 7.0 cm.</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="340"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="167"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="53" subjects_at_risk="627"/>
                <counts group_id="E8" subjects_affected="18" subjects_at_risk="101"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Induration (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Induration (moderate)=2.5 cm to 7.0 cm.</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="270"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Induration (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Induration (moderate)=2.5 cm to 7.0 cm.</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="242"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Induration (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Induration (severe) &gt;7.0 cm.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Induration (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Induration (severe) &gt;7.0 cm.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Induration (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Induration (severe) &gt;7.0 cm.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Erythema (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Erythema (any)=present at site of vaccination.</description>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="355"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="83" subjects_at_risk="360"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="180"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="319" subjects_at_risk="749"/>
                <counts group_id="E8" subjects_affected="64" subjects_at_risk="121"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Erythema (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Erythema (any)=present at site of vaccination.</description>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="265"/>
                <counts group_id="E3" subjects_affected="97" subjects_at_risk="281"/>
                <counts group_id="E4" subjects_affected="46" subjects_at_risk="153"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Erythema (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Erythema (any)=present at site of vaccination.</description>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="94" subjects_at_risk="262"/>
                <counts group_id="E3" subjects_affected="103" subjects_at_risk="274"/>
                <counts group_id="E4" subjects_affected="54" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Erythema (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Erythema (mild)=0.5 cm to 2.0 cm.</description>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="354"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="352"/>
                <counts group_id="E3" subjects_affected="76" subjects_at_risk="358"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="180"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="288" subjects_at_risk="735"/>
                <counts group_id="E8" subjects_affected="58" subjects_at_risk="116"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Erythema (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Erythema (mild)=0.5 cm to 2.0 cm.</description>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="93" subjects_at_risk="279"/>
                <counts group_id="E4" subjects_affected="44" subjects_at_risk="153"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Erythema (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Erythema (mild)=0.5 cm to 2.0 cm.</description>
                <counts group_id="E1" subjects_affected="102" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="99" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="52" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Erythema (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Erythema (moderate)=2.5 cm to 7.0 cm.</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="337"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="67" subjects_at_risk="631"/>
                <counts group_id="E8" subjects_affected="22" subjects_at_risk="104"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Erythema (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Erythema (moderate)=2.5 cm to 7.0 cm</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="268"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="252"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Erythema (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Erythema (moderate)=2.5 cm to 7.0 cm.</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="219"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="231"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Erythema (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Erythema (severe) &gt;7.0 cm.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Erythema (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Erythema (severe) &gt;7.0 cm.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Erythema (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Erythema (severe) &gt;7.0 cm.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Overfeeding of infant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1210"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1443"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella) was not available as planned; the alternate of a commercially available MMR and a commercially available varicella vaccine was administered in separate injections.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

